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Abstract
Abstract
Metabolic adaptations of cancer to scarce oxygen conditions are believed to contribute to 
the tumor promoting effect  of  hypoxia.  To assess this issue in the context  of  human 
papillomavirus induced cervical carcinogenesis, the hypoxic regulation of the glycolytic 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was investigated in non-
tumorigenic  HPV-positive  HeLa  x  fibroblast  hybrid  cells  (444),  their  tumorigenic 
segregants CGL 3 and the parental homologues IMR 90 and HeLa. 24 hours hypoxia 
lead to a transcriptional upregulation of GAPDH only in non-tumorigenic cells but not in 
their  tumorigenic  counterparts. As  shown  by ChIP analysis,  the  hypoxic  increase  of 
GAPDH was mediated by the transcription factors Net and HIF-2α. Their binding to the 
GAPDH promoter was augmented upon hypoxia exclusively in non-tumorigenic  cells. 
Moreover, GAPDH-reporter assays revealed a synergistic  trans-activating effect of Net 
and  HIF-2α  only  in  non-tumorigenic  cells  which  was  further  enhanced  by  hypoxia. 
Intriguingly,  GAPDH acts as a trigger between cell  death and survival.  To investigate 
whether the differential hypoxic regulation of GAPDH in non-tumorigenic and tumorigenic 
cells  reflects  their  resistance  to  hypoxic  conditions,  cell  viability  was  monitored  by 
determining the cellular ATP content and by FACS analysis. Indeed, the hypoxic increase 
of GAPDH correlated with a better cell viability in non-tumorigenic 444 cells. Moreover, 
FACS assays revealed different responses to hypoxia in  tumorigenic CGL 3 and HeLa 
cell.  While HeLa substantially increased apoptosis upon hypoxia, CGL 3 underwent a 
different type of cell death, possibly necrosis. Apoptosis in HeLa was likely caused by an 
altered ROS homeostasis, as this cell line did not show the expected hypoxic increase of 
oxygen radicals. In contrast, CGL 3 probably died of irreversible energy depletion, as 
they depicted the lowest ATP levels of all tested cell lines upon hypoxia. 
Another factor which might influence hypoxic survival are the viral oncoproteins E6 and 
E7. This study determined complete silencing of their expression upon hypoxia in both 
tumorigenic and non-tumorigenic cell lines. The main regulator of HPV transcription, the 
cellular transcription factor AP-1, was not responsible for this effect, as neither its dimeric 
composition nor the expression of its cognate subunits changed upon hypoxic treatment. 
Taken together,  this study indicates a dysregulation of hypoxic GAPDH expression in 
cervical  cancer  cells  which  may  influence  survival  of  energy  stress  upon  hypoxia. 
Whether  the  silencing  of  the  HPV  oncoproteins  upon  hypoxia  contributes  to  this 
observation requires further investigation.
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Zusammenfassung
Hypoxie  induziert  metabolische  Anpassungsprozesse  in  Krebszellen,  die  das 
Tumorwachstum fördern. Um diesen Zusammenhang am Model der HPV-induzierten 
zervikalen  Karzinogenese  zu  erforschen,  wurde  die  hypoxische  Regulation  des 
glykolytischen Enzyms Glyceraldehyd-3-Phosphat Dehydrogenase (GAPDH) in den 
nicht-tumorigenen  HPV-positiven  HeLa  X  Fibroblast  Zellhybriden  444,  in  deren 
tumorigenen Abkömmlingen CGL 3 und in den parentalen Zellinien IMR 90 und HeLa 
untersucht.  Es  stellte  sich  heraus,  dass  der  hypoxische  Anstieg  der  GAPDH 
Expression ausschließlich in nicht-tumorigenen Zellen zu beobachten ist. Er wird von 
den Transkriptionsfaktoren Net und HIF-2α vermittelt, die unter Hypoxie nur in nicht-
tumorigenen  Zellen  vermehrt  an  den  GAPDH  Promoter  binden.  Darüberhinaus 
zeigten  GAPDH-Reporter  Assays  eine  synergistische  Aktivierung  der  GAPDH 
Transkription  durch  Net  und HIF-2α,  die  unter  Hypoxie  weiter  verstärkt  wird  und 
ebenfalls  auf  nicht-tumorigene  Zellen  beschränkt  ist.  Um  zu  zeigen,  dass  die 
unterschiedliche  GAPDH  Regulation  unter  hypoxischen  Bedingungen  auf  eine 
Diskrepanz der hypoxischen Resistenz in tumorigenen und nicht-tumorigenen Zellen 
hindeutet,  wurde eine  FACS Analyse  und eine  Untersuchung des zellulären ATP 
Gehalts durchgeführt. Die hypoxische Induktion der GAPDH Expression in IMR 90 
und 444 korreliert tatsächlich mit einer besseren Lebensfähigkeit dieser Zellen unter 
diesen  Bedingungen.  Darüberhinaus  enthüllte  die  FACS  Analyse  eine 
unterschiedliche hypoxische Reaktion der beiden tumorigenen Zelllinien. Während 
Hypoxie in HeLa vor allem Apoptose induziert, durchlaufen CGL 3 eine andere Form 
des Zelltods, bei dem es sich um Nekrose handeln könnte. Die Apoptose in HeLa 
wird  wahrscheinlich  durch  eine  vermehrte  Empfindlichkeit  auf  Sauerstoffradikale 
hervorgerufen,  da  HeLa  nicht  die  erwartete  hypoxische  Zunahme  der 
Sauerstoffradikale  zeigt.  Im  Gegensatz  dazu  sterben  CGL 3  vermutlich  an 
irreversibler Energiedefizienz, da sie unter Hypoxie die niedrigsten ATP Werte aller 
getesteten Zellen aufweisen. Weitere Faktoren, die das hypoxische Überleben der 
Zelle beeinflussen könnten, sind die viralen Onkoproteine E6 und E7. Diese Studie 
konnte ihre Hypoxie-vermittelte Suppression nachweisen und darüber hinaus zeigen, 
dass  dies  nicht  durch  den  zellulären  Transkriptionsfaktor  AP-1  verursacht  wird. 
Weder  die  Komposition  des  dimeren  Faktors  AP-1  noch  die  Expression  seiner 
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Untereinheiten ändert sich unter Hypoxie. Zusammenfassend lässt sich sagen, dass 
Krebszellen eine Dysregulation der hypoxischen GAPDH Transkription aufweisen die 
das zelluläre Überleben unter hypoxischem Energiestress beeinflussen könnte.  In 
wieweit  sich  die  Stilllegung der  viralen  E6 und E7 Gene auf  diese Beobachtung 
auswirkt, bedarf weiterer Forschung.
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1.  Introduction 
Hypoxia denominates insufficient oxygen supply within a tissue. It is considered to be 
a major driving force for carcinogenesis (Papp-Szabò et al., 2005) and in addition a 
prognostic  factor  in  cancer  patients  indicating  a  decrease  in  disease-free  patient 
survival (Höckel  et al., 1993). Metabolic adaptations of cancer cells are thought to 
play a major role in these processes (Vander Heiden  et al., 2009). To assess this 
issue  in  the  context  of  human papillomavirus  driven  cervical  carcinogenesis,  the 
hypoxic  regulation  of  the  glycolytic  enzyme  glyceraldehyde-3-phosphate 
dehydrogenase was studied in HPV-positive tumorigenic and non-tumorigenic cell 
lines. Previously, the two transcription factors Net and HIF-2α were suggested to bind 
to the GAPDH promoter (Hitschler, 2007). The impact of these factors was studied in 
more detail, since both of them were previously associated with tumor development 
(van Riggelen  et al.,  2005; Imamura  et al.,  2009) and play a fundamental role in 
mediating the hypoxic response (Gross et al., 2008; O'Rourke et al., 1999). In recent 
years, GAPDH was shown to be involved in many non-metabolic processes (Colell et 
al., 2009). Indeed, GAPDH was suggested to act as a trigger between cell death and 
survival.  Thus, a possible link between the differential  GAPDH expression in non-
tumorigenic  and  tumorigenic  HPV-positive  cells  and  their  survival  under  hypoxic 
conditions  was  investigated.  Another  important  factor  determining  the  hypoxic 
tolerance of HPV-positive cells are the viral oncogenes E6 and E7, which exert pro-
angiogenic (Toussaint-Smith et al., 2004) and anti-apoptotic (Scheffner et al., 1990) 
effects. To shed light on these issues, their hypoxic regulation was assessed in more 
detail. 
1.1  Human papillomaviruses and cervical cancer
Human papillomaviruses (HPV)  are  non-enveloped,  double-stranded DNA viruses 
belonging to the family of Papillomaviridae. To date, almost 200 different subtypes of 
HPVs are known and about 40 of them infect the anogenital tract causing benign 
lesions and sometimes malignancies (Bernard et al., 2010). Tumorigenic progression 
is  associated  with  so-called  “high-risk”  HPV  types  16,  18  and  31,  which  are 
responsible  for  more  than  95  %  of  cervical  cancers  (Muñoz  et  al.,  2003).  The 
7
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transforming capacity of these types is mediated by the viral oncogenes E5 (Straight 
et  al.,  1993),  E6  and  E7  (Münger  et  al.,  1989).  Especially  the  latter  ones  bear 
oncogenic  potential,  since  they  promote  the  ubiquitin-proteasome  dependent 
degradation or inactivation of the cellular tumor-suppressors p53 (Scheffner  et al., 
1990) and pRb (Boyer  et al., 1996), respectively. Furthermore, they stimulate neo-
vascularization (Chen et al., 2007), which is important for early tumor angiogenesis. 
Transfection  of  primary  human  keratinocytes  with  high-risk  E6  and  E7  genes  is 
sufficient  for  their  immortalization  in  vitro.  However,  tumorigenic  progression  to 
cervical  cancer  requires  further  cancer  promoting  events  like  constitutive  c-fos 
expression (Soto et al., 1999).
1.1.1  HPV genome organization and viral life cycle
HPVs harbor a circular double-stranded DNA genome of about 8 kb which can be 
divided into three major regions:
● The 850 bp spanning upstream regulatory region (URR) (Fig. 1.1) harbors the 
origin of viral DNA replication as well as the epithelium-specific enhancer and 
the proximal promoter driving the transcription of the early genes (Butz and 
Hoppe-Seyler, 1993).
● The early region encodes six open reading frames (ORFs) (Fig. 1.1), among 
them E1 and E2 playing a role in viral DNA replication and the regulation of 
early  transcription  (Del  Vecchio  et  al.,  1992;  Bouvard  et  al.,  1994).  E4  is 
involved in the breakdown of cellular integrity during viral release (Doorbar et 
al.,  1991).  The  viral  oncogenes  E5,  E6  and  E7  are  associated  with  cell  
transformation  and  immortalization.  An  additional  promoter,  regulating  the 
expression of the late genes, is located within the E7 ORF.
● The late region encodes the viral capsid proteins L1 and L2 necessary for the 
assembly of viral particles (Zhou et al., 1991).
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Fig.  1.1: Genome  organization  of  human  papillomaviruses 
(represented by HPV 18).  The genome can be subdivided in three 
major regions: the upstream regulatory region (URR), the early region 
(E1 – E7) and the late region (L1 and L2).
HPVs infect  dividing  basal  epithelial  cells.  Heparan sulfate  proteoglycans (Shafti-
Keramat, 2003) and certain integrins (Evander  et al., 1997) at the host cell surface 
mediate viral docking and their subsequent endocytic inclusion (Day  et al.,  2003). 
After viral disassembly, the L2 protein triggers the nuclear translocation of viral DNA 
(Day et al., 2004). The viral genome persists as a stable episome in basal epithelial 
cells which replicates together with cellular DNA during S-phase (Gilbert and Cohen, 
1987).  In  this  part  of  the  viral  life  cycle,  only  the  early  genes  are  expressed. 
Progression of keratinocytes into suprabasal layers induces  transcription of the late 
viral genes enabling the assembly and release of viral particles (Bodily and Meyers,  
2005). The continued expression of E6 and E7 prevents terminal differentiation of the 
host cell and keeps the keratinocytes in cell cycle, resulting in the formation of benign 
lesions (Sherman et al., 1997). During long-term infection, episomal HPV DNA tends 
9
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to integrate into the host genome, leading to the disruption of several ORFs (Schwarz 
et  al.,  1985).  Among  them are  E2,  L1  and  L2  which  disables  formation  of  viral  
particles. 
1.1.2  Transcriptional regulation of the early HPV genes
Regulation  of  viral  transcription  is  especially  important  for  HPVs,  as  it  decisively 
contributes to their cell-type specificity. As mentioned above (chapter 1.1.1), the viral 
URR controls  the  transcription  of  the  early genes.  It  can be subdivided into  two 
domains: the tissue specific enhancer and the early promoter. 
The  early  promoter,  which  is  referred  to  as  p105  in  HPV18 and  p97  in  HPV16 
mediates the recruitment of RNA polymerase II  and the associated transcriptional 
machinery  (Thierry  et  al.,  1987;  Garcia-Carranca  et  al.,  1988).  The  main  cis-
regulatory elements are a tandem repeat of E2 binding-sites overlapping with an Sp1 
binding site near the viral TATA box. It is believed, that during the episomal phase of  
the viral life-cycle, binding of viral E2 to the early promoter prevents interaction with 
Sp1, thus suppressing transcription of the early oncogenes E6/E7 (Tan et al., 1994). 
Integration  of  the  viral  DNA into  the  host  genome  causes  loss  of  E2  and  thus 
subsequent  upregulation  of  E6/E7.  Other  cellular  factors  which  bind  to  the  early 
promoter  are  activator  protein  1  (AP-1),  Ying  Yang  1  (YY-1)  and  glucocorticoid 
receptors.  Interestingly,  the  AP-1 binding  site  overlaps  with  several  YY-1  binding 
sites, which enables the transcriptional inhibitor YY-1 to quench AP-1 mediated trans-
activation of  early gene transcription (O'Connor et al., 1996). 
The HPV enhancer mediates the epithelial specificity of HPV transcription. Although 
the  exact  mechanism  is  not  yet  clear,  the  composition  and  interplay  of  cellular 
transcription  factors  at  the URR substantially contributes to  this  effect.  The most 
prominent ones are Oct-1 (octamer binding protein 1), NF-1 (nuclear factor 1), PR 
(progesterone receptor), TEF-1 (Transcription enhancer factor 1), AP-1 and nucleolin. 
The roles of Oct-1 and NF-1 are highly dependent on the HPV type (Butz and Hoppe-
Seyler, 1993; O'Connor and Bernard, 1995): Both factors seem to be essential for 
HPV16 but dispensable for HPV18. Transcriptional stimulation by the progesterone 
receptor is dependent on the progesterone type (Chen et al., 1996). The keratinocyte 
specificity of viral transcription is mediated by TEF-1, AP-1 and to some extent by 
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nucleolin. The transcription factor TEF-1 is believed to mediate cell specificity of HPV 
transcription by the recruitment of  tissue-specific co-activators (Ishiji  et al.,  1992). 
Similarly, different compositions of the dimeric transcription factor AP-1 regulate the 
HPV transcription according to the cellular background. Mutation of the AP-1 binding 
site inhibits early transcription, making AP-1 a central  trans-activator of viral  gene 
expression.  The important  role  of  AP-1 will  be outlined in chapter  1.1.3.  A factor 
mediating the specificity of HPV transcription for dividing cells is nucleolin, whose 
expression correlates with cell proliferation rates (Grinstein et al., 2002). 
In conclusion, the HPV enhancer is activated by the presence of a cell type specific 
set  of  transcription factors.  Bouallaga and colleagues propose a model,  where  a 
keratinocyte  specific  composition  of  the  AP-1  complex  is  prerequisite  for  the 
formation  of  an  enhanceosome  over  the  HPV  URR.  The  enhanceosome  would 
accordingly consist of other transcription factors mediating efficient and host specific 
HPV transcription (Bouallaga et al., 2000).
1.1.3  The central role of AP-1
AP-1 is a dimeric transcription factor composed of Jun, Fos and ATF family members. 
Jun  proteins  either  form  homodimers  or  heterodimers  with  Fos  and  ATF  family 
members. The composition of the AP-1 complex is regulated by various extracellular 
stimuli. Its trans-activating properties depend on the availability and post-translational 
modification of AP-1 subunits and the interaction with co-factors. The AP-1 complex 
composition determines  binding to two different DNA response elements, the TRE 
(TPA  responsive  element)  and  the  CRE  (calcium/cAMP-responsive  element). 
Thereby AP-1 enables the specific regulation of  a certain  set  of  genes in  a  very 
selective manner (Shaulian, 2010; Milde-Langosch, 2005). 
AP-1  is  essential  for  HPV expression  since  mutation  of  either  AP-1  binding  site 
completely abrogates HPV transcription (Butz and Hoppe-Seyler, 1993). Similarly, the 
antioxidants  curcumin  and  pyrrolidine  dithiocarbamate  (PDTC)  inhibit  HPV 
expression by abolishing binding of AP-1 to the HPV URR (Rösl et al., 1997; Prusty 
and Das, 2005). In addition, the composition of the AP-1 complex highly influences its 
effect on HPV transcription. In this regard, the Fos family members Fra-1 and c-Fos 
11
1. Introduction 
play an important role. In non-malignant cells, the prevalent AP-1 composition is Jun-
Fra-1, which is not able to efficiently trans-activate early HPV transcription (Soto et 
al., 1999). Cervical carcinogenesis is accompanied by an increased expression of the 
oncogene c-Fos and almost complete loss of Fra-1, which leads to a shift in the AP-1 
composition (De Wilde et al., 2008). In tumorigenic HPV-positive cells, the prevalent 
AP-1 composition is c-Jun – c-Fos (Fig. 1.2) leading to a high expression of E6/E7 
genes.  
The constitutive expression of c-fos in cervical cancer is mediated by changes in its 
transcriptional  regulation.  The  ternary  complex  factor  Net  is  bound  to  the  c-fos 
promoter of non-malignant cells leading to a suppression of  c-fos transcription. In 
contrast, Net is almost absent in malignant cells resulting in a high transcription of c-
fos. Knock-down of Net in non-malignant cells promotes reexpression of  c-fos  (van 
Riggelen et al., 2005). 
Fig.  1.2:  The  ratio  of  Fos  an  Fra-1  changes 
during malignancy
An attractive model to study the impact of AP-1 composition on HPV transcription 
and cervical carcinogenesis are somatic cell hybrids. Fusion of the HPV18-positive 
cervical cancer cell line HeLa with non-tumorigenic lung fibroblasts resulted in a non-
malignant   hybrid  (444).  Upon  long-term  cultivation,  spontaneous  tumorigenic 
segregants (CGL 3) arose (Stanbridge, 1984) (Fig. 1.3). Non-tumorigenic 444 cells 
express  high  levels  of  Fra-1  which  changes  in  favor  to  c-Fos  in  CGL  3.  The 
importance of the correlation is emphasized by the fact that ectopic overexpression 
of c-Fos in 444 induces tumorigenicity (Soto et al., 1999). However, over-expression 
of  Fra-1  in  CGL 3  neither  reversed  the  tumorigenic  phenotype  nor  changed  the 
composition of the AP-1 complex (De Castro Arce et al., 2004). 
12
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Fig. 1.3: Fusion of HeLa and lung fibroblasts results in non-malignant hybrids (444). Upon 
long- term cultivation, rare tumorigenic segregants (CGL 3) arose. 
1.1.4  The Ets transcription factor family
The prototype of the Ets (E26 transformation specific) family,  the oncogene  v-ets, 
was first described in 1983 causing both erythroblastic and myeloblastic leukemias in 
chicken (Leprince et al., 1983). Since then, many cellular homologues were isolated 
(Oikawa and Yamada, 2003) – the family of ets genes. Today, this family comprises 
approximately  30  members.  The  characteristic  feature  of  Ets  factors  is  their  
evolutionary  conserved  Ets  domain,  a  stretch  of  about  85  amino  acids  which 
facilitates the binding to the EBS (Ets binding site) in the target promoters (Graves 
and Petersen, 1998). However it is still mainly unclear, what determines the specific  
recruitment of an Ets factor to a certain gene. Although multiple Ets factors can target  
a specific EBS (Hollenhorst et al., 2007), there is evidence that interaction with other 
transcription  factors  mediates  gene  specific  recruitment  of  a  certain  Ets  factor 
(Aprelikova et al., 2006; Hollenhorst et al., 2009). Ets family proteins are transcription 
factors which integrate signal transduction cascades into the nucleus. Thus, post-
translational  modifications  play  an  important  role  and  influence  subcellular 
localization,  trans-activating  properties,  DNA  binding,  recruitment  of  interaction 
partners and protein stability (Sharrocks et al., 2001). Ets factors play a crucial role in 
apoptosis,  growth,  development,  differentiation  and  oncogenic  transformation 
(Oikawa and Yamada, 2003). 
One of the best studied subfamilies of Ets factors are the ternary complex factors 
(TCFs).  Their  characteristic  feature  is  the  formation  of  ternary complexes  with  a 
13
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serum  response  factor  (SRF)  dimer  over  a  serum  response  element  (SRE),  a 
phenomenon which was first described at the c-fos promoter (Shaw et al., 1989). By 
now, three TCFs have been identified: Elk-1 (Ets-like transcription factor 1) (Rao et 
al., 1989), Sap-1 (SRF accessory protein 1)/Elk-4 (Dalton and Treisman, 1992) and 
Net (new Ets transcription factor)/Erp (ets related protein)/Sap-2/Elk-3 (Giovane  et 
al.,  1994).  The biological  roles of the TCF are still  unclear.  Elk-1 knock-out mice 
display only minor neuronal defects and are viable (Cesari et al., 2004). Sap-1 knock-
out mice do not show a specific phenotype (Sadakata  et al., 2009). However, this 
could be explained by a high redundancy of Sap-1 and Elk-1 as recently indicated for 
thymocyte  development  (Costello  et  al.,  2010).  Net  knock-out  results  in  severe 
vascular and lymphatic abnormalities and mice die of respiratory failure shortly after 
birth (Ayadi et al., 2001). 
1.1.5  Physiological role of Net and the impact on tumorigenesis
As mentioned above, Net differs from the other ternary complex factors because its 
function seems to be indispensable for normal development. In the following section, 
the  current  knowledge  about  the  role  of  Net  in  transcriptional  regulation  will  be 
outlined.
Net acts as a negative regulator of the oncogene c-fos in a SRF-dependent manner 
(van Riggelen et al., 2005). Overexpression of Net seems to retard cell proliferation 
in a c-fos positive pancreatic cancer model (Li et al., 2008), making Net a key player 
in  c-fos-  driven  tumorigenicity.  Similarly,  loss  of  Net  and  the  concomitant  c-fos 
upregulation is an important event during cervical carcinogenesis (van Riggelen  et 
al., 2005; de Wilde et al., 2008)
Accumulating evidence suggests a role of Net during angiogenesis. Expression of 
VEGF, a potent activator of neo-vascularization, is negatively controlled by Net via an 
indirect  mechanism (Zheng  et  al., 2003).  However,  Net  can exert  pro-angiogenic 
properties suppressing the transcription of plasminogen activator inhibitor (PAI-1) in 
mice (Buchwalter  et al., 2005) and Egr-1 in humans (Ayadi  et al., 2001). PAI-1, a 
negative regulator of fibrinolysis, retards cell migration and wound closure. Egr-1 acts 
as  a  negative  regulator  of  angiogenesis.  Indeed,  sustained  Egr-1  expression 
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abrogates angiogenesis and thereby prevents tumor growth in murine fibrosarcomas 
(Lucerna  et al., 2006). Overall, the role of Net in angiogenesis is still unclear, as it 
inhibits the expression of both pro- and anti-angiogenic mediators.
Furthermore,  Net  participates  in  the  inflammatory  response.  Net  was  shown  to 
repress  the  transcription  of  two  inflammatory  mediators,  nitric  oxide  synthase  2 
(NOS2) (Chen et al., 2003) and heme oxygenase 1 (HO-1) (Chung et al., 2006). In 
addition  to  its  anti-inflammatory  properties,  HO-1  stimulates  angiogenesis. 
Overexpression  of  HO-1 promotes pancreatic  cancer  progression  and metastasis 
(Sunamura et al., 2003).
Emerging evidence suggests an important function of Net in the hypoxic response. 
Gross and colleagues report in a microarray study, that 75 % of Net target genes are 
in common with one of the main regulators of the hypoxic response, HIF-1α. This 
suggests widely overlapping functions. In addition, Net and HIF-1α are both regulated 
by a group of  prolyl-hydroxylase-domain containing proteins (PHD), which act as 
sensors of cellular oxygen content (Jaakkola et al., 2001; Gross et al., 2007). Thus, 
Net and HIF-1α not only share their target genes, but they are regulated by common 
signaling pathways, too.
1.1.6  Hypoxia and cancer
Hypoxia, defined as inadequate oxygen supply (≤ 5 % O2) of a tissue, is found in a 
variety of pathophysiological conditions like stroke (Sulter et al., 2000), inflammation 
(Murdoch et al., 2005) and carcinogenesis (Bertout et al., 2008). Red blood cells are 
responsible for distributing the oxygen throughout the body. Diffusion of oxygen into 
the neighboring tissue enables an adequate oxygen supply within 150 μm distance of 
the  blood vessel   (Helmlinger  et  al.,  1997).  Thomlinson and colleagues reported 
already  in  the  1950s  that  viable  tumor  cells  were  only  found  in  the  direct 
neighborhood  of  blood  vessels.  Tumor  areas  distant  from arteriolar  supply  were 
necrotic. In fact, there is an oxygen gradient from well oxygenated cells next to the 
vessels to anoxic areas were oxygen is almost absent. Today it is generally accepted 
that cancer cells are exposed to repeated cycles of hypoxia due to the chaotic and 
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rapidly changing tumor vascularization (Brown, 1979). However, the duration of these 
cycles largely varies. Thus, scientists discriminate between “acute hypoxia” lasting 
from minutes to hours and “chronic hypoxia” lasting from hours to days. 
In general, hypoxia is associated with decreased survival of patients in a variety of 
cancer types like cervical (Höckel  et al., 1993), head and neck (Nordsmark  et al., 
2005) and soft-tissues sarcoma (Nordsmark et al., 2001). The specific contributions 
of the different hypoxia characteristics to the aetiopathology of cancer are however 
still under debate.  Acutely hypoxic cells were shown to quickly reenter the cell cycle 
upon reoxygenation in a p53-dependent manner (Pires et al., 2010). Reoxygenation 
of these cells is accompanied by a burst of reactive oxygen species (ROS), which 
induces massive DNA-damage and subsequently p53 accumulation and apoptosis. 
However, most cancers display an impaired p53 functionality, which enables a quick 
resumption of the cell cycle in the presence of DNA damage (Aguilera and Gomez-
Gonzales, 2008). Chronic hypoxia was as well reported to drive a more tumorigenic 
phenotype. When comparing a chronic and an acute hypoxic prostate cancer model 
with  its  parental,  tumorigenic  cell  line,  the  chronic  hypoxia  model  displayed  the 
highest clonogenic capacity and the strongest VEGF secretion (Alqawi et al., 2007). 
In addition, only prolonged hypoxic treatment of a neuroblastoma model resulted in 
reduced susceptibility to chemotherapeutic drugs (Hussein et al., 2006). In line with 
these observations, Ameri and colleagues demonstrated in a breast cancer model, 
that circulating tumor cells, causative for metastasis, displayed an increased colony 
formation  under  chronic  hypoxia,  indicating  a  preceding  adaptation  to  prolonged 
oxygen deprivation (Ameri et al., 2010).  
Overall, the cellular consequences of hypoxia regarding tumorigenicity and cellular 
survival might be highly dependent on the duration and extent of oxygen deprivation 
as well as the genetic background of the host. To illustrate the hypoxic response, its 
key players will be highlighted in the following section.
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1.1.7  Keyplayers of the hypoxic response
Hypoxia inducible factors (HIF)
The  best  studied  mediators  of  the  hypoxic  response  are  the  hypoxia  inducible 
factors.  These  dimeric  transcription  factors  belong  to  the  basic  Helix-Loop-Helix 
(bHLH)  protein  family  and  consist  of  an  oxygen-sensitive  alpha  subunit  and  a 
constitutively  expressed  beta-subunit  (HIF-1β,  also  known  as  Aryl  Hydrocarbon 
Receptor Nuclear Translocator) (Wang  et al., 1995). To date, three different alpha-
subunits have been described: The best studied and ubiquitously expressed is HIF-
1α. Basic studies describing its hypoxic trans-activating capacity were conducted on 
the EPO promoter (Wang and Semenza, 1993b).  Since then, two other members 
were  discovered  which  are  encoded  in  separate  genes.  HIF-2α  shares  48 % 
homology with HIF-1α (Hu et al., 2007) but it is expressed only in certain tissues and 
cancer types (Wiesener  et al.,  2003).  Both, HIF-1α and HIF-2α harbor two  trans-
activation  domains  (TAD)  which  enable  them  to  strongly  induce  transcription  of 
hypoxia-inducible genes. In contrast,  the third member HIF-3α holds only  the N-
terminal TAD, thus exhibiting a low trans-activation potential. When competing with 
the  other  alpha-subunits,  it  was  shown to  repress  transcription  of  the  respective 
target genes (Hara et al., 2001).
As  mentioned  above,  all  HIFα  subunits  are  sensitive  to  oxygen-dependent 
degradation  which  is  mediated  by  their  shared  oxygen-dependent  degradation 
domain  (ODD).  When  oxygen  levels  rise,  a  family  of prolyl-hydroxylase-domain 
containing proteins (PHD) mediates the hydroxylation of distinct prolin residues (Fig. 
1.5). This enables the interaction of HIFα subunits with the E3 ubiquitin-ligase VHL 
(von-Hippel-Landau factor) and subsequent proteasomal degradation (Jaakkola et al. 
2001;  Appelhoff  et  al.,  2004).  Under  hypoxic  conditions,  PHDs lack the essential 
oxygen  for  hydroxylation.  In  addition,  they  themselve  are  subject  of  enhanced 
proteasomal degradation mediated by the E3 ubiquitin-ligases Siah 1 and Siah 2 
(“Seven in absentia homologues” 1 and 2) (Nakayama et al., 2004). 
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In the case of HIF-1α,  the activity of  the c-terminal  TAD can be fine-tuned in an 
oxygen  dependent  manner.  Factor  inhibiting  HIF-1  (FIH)  hydroxylates  a  distinct 
asparagine residue in HIF-1α leading to the inhibition of the c-terminal TAD (Lando et 
al., 2002) (Fig 1.5).  HIF-2α is as well hydroxylated by FIH, but there is only a minor 
effect on its trans-activating potential (Yan et al., 2007). 
Presence of the viral oncogenes E6 and E7 of both high- and low-risk HPVs was 
shown to enhance stabilization of HIF-1α upon hypoxia, resulting in the increased 
activation of HIF-1 target genes (Nakamura et al., 2009; Tang et al., 2007).
Fig. 1.5: Oxygen dependent regulation of Hypoxia-inducible factors.  Under normoxic 
conditions, PHDs hydroxylate two proline (Pro) residues of the HIFα subunits. This facilitates 
ubiquitination  by  the  VHL  and  subsequent  proteasomal  degradation.  In  contrast,  FIH 
mediates  oxygen  dependent  fine-tuning,  especially  of  HIF-1α.  By  hydroxylating  an 
asparagine  residue,  FIH  blocks  the  activity  of  the  c-terminal  TAD (C-TAD)  domain  and 
enables a distinct trans-activation of genes more susceptible to the N-terminal TAD (N-TAD).
All HIF dimers were shown to bind to hypoxia-responsible elements (HRE) located at 
the promoter of hypoxia sensitive genes. The target genes of HIF-1 and HIF-2 are 
mainly redundant.  However,  growing evidence suggests,  that  both factors  indeed 
vary  in  the  specificity  to  distinct  groups  of  target  genes.  HIF-1  was  shown  to 
preferentially trans-activate glycolytic genes (Hu et al., 2003), while HIF-2 was shown 
to  induce for  example  transforming  growth  factor  α  (TGFα)  (Raval  et  al.,  2005), 
octamer  binding  transcription  factor 4  (Oct-4)  (Covello  et  al.,  2006)  and  vascular 
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endothelial growth factor receptor 2 (VEGFR2) (Kappel et al., 1999). The target gene 
specificity is conferred by two main factors: the duration and extent of hypoxia as well  
as the cellular background and the availability of co-factors. Concerning the influence 
of oxygen availability, HIF-1α preferentially mediates the acute response to hypoxia, 
while  HIF-2α  takes  over  its  function  in  case  of  prolonged  hypoxia  (Holmquist-
Mengelbier et al., 2006). In the context of co-factor mediated target gene specificity, 
the transcription factor family of Ets factors plays an important role: Ets-1 (Elvert et 
al.,  2003)  and  Elk-1  (Aprelikova  et  al.,  2006)  recruit  HIF-2α  to  target  genes.  In 
contrast, GATA-2 was shown to be required for HIF-1 recruitment (Yamashita et al., 
2001). This mechanism facilitates target gene specificity in an elegant way despite 
the redundant DNA binding motif of HIF-1 and HIF-2. 
Reactive oxygen species (ROS)
Accumulating evidence suggests that mitochondria are one of the central  oxygen 
sensors of the cell. It seems that reactive oxygen species produced by mitochondria 
upon oxygen deprivation are essential  for  the hypoxic  response.  Indeed,  hypoxic 
induction of HIFs is abolished by antioxidant treatment. In a similar way, mitochondria 
depleted cells fail to induce HIFs upon hypoxia. (Chandel et al., 1998)
The main source for mitochondrial ROS is complex III, where the enzyme ubiquinone 
(co-enzyme Q) is oxidized in a two-step process. In the intermediate step, radical 
ubisemiquinone is formed, which is capable of donating its free electron to molecular 
oxygen (Turrens  et al.,  1985). The resulting mitochondrial radical, the superoxide-
anion  (O2-),  is  subsequently  distributed  from  the  mitochondria  to  the  cytoplasm 
(Muller et al., 2004). Hypoxia is generally accompanied by an increase of ROS. The 
underlying  mechanism  is  however  still  under  debate.  Mitochondrial  peroxidases 
which  are  able  to  neutralize  the  radicals  within  the  mitochondria,  may display a 
reduced activity under hypoxia (Murphy 2009). 
ROS exert  a multitude of cellular effects,  many of them linked to carcinogenesis. 
Most  apparently,  they  induce  multiple  forms  of  DNA  damage  which  increases 
genomic instability in cancer cells. In addition, ROS regulate the activity of several 
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kinases,  among  them  extracellular  signal  regulated  kinase  (ERK1/2)  and 
phosphoinositide 3-kinase (PI3K) (Triantafyllou  et al., 2006) whose dysregulation is 
considered to promote tumorigenesis.
1.2  Metabolism and cancer
Carcinogenesis is accompanied by a shift in energy metabolism. In the presence of 
sufficient amounts of oxygen, most differentiated cells optimize their metabolism to 
yield maximal ATP and minimal lactate, a ratio which changes only in case of scarce 
oxygenation. Already in the 1920s, Otto Warburg observed that most cancer cells 
catabolize glucose to lactate even in the presence of sufficient amounts of oxygen 
which is termed “aerobic glycolysis”. Concerning the resulting ATP, aerobic glycolysis 
seems to be much less efficient than mitochondrial oxidative phosphorylation: while 
the latter one results in 36 M ATP, a conversion of glucose to lactate renders only 2 M 
ATP (Lehninger et al., 1993). Recently, scientists began to unravel the advantage of 
aerobic glycolysis for cancer cells. Several glycolytic intermediates are precursors for 
the synthesis of lipids, amino acids and nucleotides. All of these macromolecules are 
essential for highly proliferating cancer cells, since they need to double their biomass 
for each cell division.
An  important  example  is  the  pentose  phosphate  pathway.  It  reroutes  glycolytic 
intermediates to fuel the production of NADPH and ribose-5-phosphate which are 
precursors for fatty acid and nucleotide synthesis, respectively. Furthermore, NADPH 
is one of the most important co-factors of  ROS-neutralizing enzymes (Pollack et al., 
2007). ROS induced DNA damage is especially harmful during proliferation and may 
be causative for the accumulation of mutations. 
To allow a rerouting of glycolytic intermediates into the pentose phosphate pathway, 
cancer  cells  take  control  over  their  glycolytic  flux  by  regulating  the  last  step  of 
glycolysis: the conversion of phosphoenolpyruvate to pyruvate by pyruvate kinase. In 
contrast to normal cells, which use the highly active pyruvate kinase isoenzyme 1 
(PK-1M), cancer cells preferentially express the substrate-inducible variant PK-2M 
which  displays  a  low  activity  and  can  be  inhibited  by  tyrosine  kinase  signalling 
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(Christofk et al., 2008). The preferential expression of PK-2M enables a reduction of 
glycolytic throughput. This leads to the accumulation of glycolytic intermediates and 
induces their redirection into the pentose phosphate pathway. 
How do cancer cells reprogram their metabolism? Vander Heiden and colleagues 
propose a  model,  where  oncogenic  pathways  promote  a  proliferative  metabolism 
including cell-autonomous nutrient uptake (Vander Heiden et al., 2009). In contrast, 
tumor  suppressive  signaling  is  thought  to  shut-down  anabolic  processes.  A well  
studied example for this theory is the tumor suppressor p53. Its target gene TIGAR 
controls the rerouting of glycolytic intermediates into the pentose phosphate pathway 
(Bensaad et al., 2006). Another example for oncogenes which reprogram the cellular 
metabolism  is  c-myc,  which  is  involved  in  glutamine  metabolism.  Glutamine 
withdrawal of c-myc transformed cells in fact induces apoptosis (Yuneva et al., 2007).
1.3  The manifold properties of GAPDH
For a long time,  GAPDH was simply seen as a central  enzyme of  the glycolytic 
pathway,  catalyzing  the  oxidation  of  glyceraldehyde-3-phosphate  to  1,3-
biphosphoglycerate  (Racker  et  Krimsky,  1952).  GAPDH is  often  referred  to  as  a 
housekeeping gene due to its ubiquitous and high expression levels. Today, GAPDH 
is known to play a role in a variety of cellular functions. Indeed, most of the recently  
discovered properties of GAPDH are  unrelated to its glycolytic function. The enzyme 
is involved in cytoskeletal dynamics (Huitorel and Pantaloni, 1985), it regulates RNA 
stability, thus controlling protein expression (Zhou et al., 2008) and it acts as a cell-
cycle dependent transcription factor (Zheng et al., 2003). 
More  intriguingly,  GAPDH  serves  as  a  trigger  between  cell  death  and  survival. 
Nuclear accumulation of GAPDH directly precedes induction of apoptosis which can 
be efficiently antagonized by over-expression of the anti-apoptotic Bcl2 (Dastoor and 
Dreyer 2001; Maruyama  et al.,  2001).  Indeed, nuclear translocation of GAPDH is 
tightly regulated, as the enzyme itself does not harbor a nuclear localization signal.  
Upon apoptotic  stimuli,  GAPDH interacts  with  Siah1 which  facilitates  subsequent 
nuclear transport (Hara  et al.,  2005).  Here, GAPDH acts as a transcription factor 
recruiting  the  co-activator  CBP/p300.   This  enhances  CBP/p300  trans-activation 
capacity and leads to the activation of pro-apoptotic mediators like p53 (Sen et al., 
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2008). Siah-1 in turn is stabilized by GAPDH which increases Siah1 nuclear levels 
and accelerates proteasomal degradation of its nuclear targets. In addition, GAPDH 
exerts  pro-apoptotic  functions  in  the  cytoplasm.  The  active  site  of  GAPDH 
dehydrogenase activity is highly susceptible to oxidation (Hwang et al., 2009). Thus it 
is not surprising, that GAPDH acts as a trigger in oxidant induced cell death: Severe 
oxidation  can  induce  the  formation  of  inter-molecular  disulfide-bonds,  leading  to 
amyloid-like GAPDH aggregation  and subsequent  cell  death.  On the other  hand, 
inactivation  of  GAPDH  blocks  the  glycolytic  flux  which  leads  to  a  rerouting  of 
glycolytic  intermediates  into  the  pentose  phosphate  pathway  and  fuels  the  anti-
oxidant defense (Ralser et al., 2007). 
Indeed, GAPDH has several pro-survival functions. This notion is supported by the 
fact that cancers often display an over-expression of GAPDH, which was associated 
with poor patient outcome (Révillion et al., 2000; Lavallard et al., 2009). Tumor cells 
often depict defects in the apoptotic machinery, rendering them resistant to apoptotic 
triggers. Under these circumstances, GAPDH can prevent caspase independent cell 
death (CICD) (Colell et al., 2007) which is characterized by mitochondrial membrane 
permeabilization  and  subsequent  cell  death  in  the  absence  of  caspase  activity. 
GAPDH was shown to prevent CICD in two ways: it  enhances the expression of 
autophagic genes to clear damaged mitochondria and enables the maintenance of 
cellular  energy homeostasis  via  its  glycolytic  properties.  In  addition,  GAPDH can 
inactivate the mTOR pathway, an important trigger for autophagy (Lee et al., 2009). 
Another  pro-survival  function  is  assigned  to  the  genome  protecting  properties  of 
GAPDH. Its binding to the chromosomal telomeres is required for their maintenance 
and  might  be  associated  with  cellular  immortalization  (Sundaraj  et  al.,  2004). 
Additionally,  GAPDH stabilizes the apurinic endonuclease 1 (APE1). This enzyme 
repairs drug- or oxidant-induced DNA damages thus enabling the maintenance of 
genomic integrity under harsh environmental conditions (Azam et al., 2008). 
Taken  together,  the  function  of  GAPDH  is  highly  dependent  on  the  cellular 
background and its post-translational modifications. Colell and colleagues propose a 
GAPDH  mediated  metabolic  checkpoint,  which  triggers  pro-apoptotic  and  pro-
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survival machineries. Overcome this checkpoint would be beneficial in the process of 
tumorigenesis, when cells are getting more resistant to oxidative stress and scarce 
nutrient conditions. 
2.  Objectives
During  cervical  carcinogenesis,  hypoxia  drives  the  development  of  a  more 
aggressive cancer phenotype which is accompanied by metabolic alterations (Höckel 
et al.,  1993; Vander Heiden  et al., 2009). Indeed, the expression of the glycolytic 
enzyme GAPDH is  often  deregulated  in  cancers  but  the  underlying  mechanisms 
remain unknown (Révillion et al., 2000). Interestingly, the two transcription factors Net 
and  HIF-2α  associated  with  carcinogenesis  and  cellular  hypoxic  response  were 
suggested to  bind  to  the  GAPDH promoter  (Hitschler,  2007).  This  study aims to 
elucidate,  whether  they  are  involved  in  the  frequently  observed  deregulation  of 
GAPDH during  tumorigenesis.  Considering  the  crucial  role  of  this  enzyme  as  a 
trigger between cell death and survival (Colell et al., 2009), GAPDH impacts cellular 
resistance to metabolic stress caused by hypoxia. Thus, as a second objective, the 
hypoxic  tolerance  of  tumorigenic  and  non-tumorigenic  HPV-positive  cells  will  be 
investigated. Another important factor affecting the hypoxic response are the viral 
oncoproteins  E6  and  E7  which  exert  anti-apoptotic  and  pro-angiogenic  effects 
(Scheffner et al., 1990; Toussaint-Smith et al., 2004). To shed light on this issues, the 
hypoxic regulation of these oncogenes will be assessed in more detail.
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3.  Material and Methods
3.1  Abbreviations
Ad 5 Adenovirus 5
AGE Agarose gel electrophoresis
AMPK AMP activated protein kinase
AP-1 Activator protein 1
APS Ammonium persulfate
ARNT Aryl hydrocarbon receptor nuclear translocator
ATF Activating transcription factor
ATM Ataxia telangiectasia mutated
ATP Adenosine 5-triphosphate
ATR Ataxia telangiectasia and Rad3-related
bHLH Basic helix-loop-helix
BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
bp Basepair 
BSA Bovine serum albumin 
C-fos human homolog of the Finkel-Biskis-Jinkins osteosarcoma 
virus oncogene 
CAMKK2 Calcium-calmodulin-dependent kinase 2
cAMP cyclic adenosine monophosphate
CBP CREB-binding protein
ChIP Chromatin immunoprecipitation
CICD Caspase independent cell death
CRE Calcium/cAMP-responsive element
DAPI 4′,6-Diamidin-2-phenylindol
DEPC Diethyl-pyrocarbonate
DHE Dihydroethidium
DMEM Dulbecco's Modified Eagle's Medium
DNA Deoxyribonucleic acid 
dNTP 2 -Deoxynucleosine-5 -triphosphate 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EBS Ets binding site
ECL-Reagent Enhanced chemiluminescence reagent 
EDTA Ethylenediaminetetraacetic acid 
Egr-1 Early growth response protein-1
EGTA Ethylene glycol tetraacetic acid
Elk-1 Ets-like transcription factor 1
EMSA Electrophoresis mobility shift assay
ERK Extracellular signal-regulated kinase
Erp Ets related protein
Ets E26 transformation-specific
FACS Fluorescence activated cell sorting
FCS Fetal calf serum 
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Fra-1 Fos related antigene 1
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GFP Green fluorescent protein
HBS HEPES buffered saline
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIF Hypoxia inducible factor
HIPK2 Homeodomain-interacting protein kinase 2 
HO-1 Heme oxygenase 1
HPV Human papillomavirus 
HRE Hypoxia response element
HRP Horse radish peroxidase 
IgG Immunoglobuline G
IP Immunoprecipitation
Kbp Kilobasepair 
KDa Kilodalton
LAR II Luciferase assay reagent II
LB Luria Bertoni
MAPK Mitogen activated protein kinase
MOPS Morpholine propanesulfonic acid
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin
mTORC1 mTOR complex 1
Net New Ets transcription factor
NF-1 Nuclear factor 1
NOS2 Nitric oxide synthase 2
NP-40 Nonidet P-40
NTP Nucleoside triphosphate
Oct-1 Octamer-binding transcription factor 1
ODD Oxygen-dependent degradation domain
ORF Open reading frame
PAI-1 Plasminogen activator inhibitor 1
PBS Phosphate buffered saline
PCR Polymerase chain reaction 
pDNA Plasmid DNA
PDTC Pyrrolidine dithiocarbamate
PHD Prolyl hydroxylase
PI3K Phosphoinositide 3-kinase
PIAS1 Protein inhibitor of activated STAT1
PML Promyelocytic leukaemia tumor suppressor
PR Progesterone receptor
PVDF Polyvinyldifluoride
RIPA Radioactive immunoprecipitation assay
RLU Relative luciferase units
RNA Ribonucleic acid
ROS Reactive oxygen species
RT-PCR Reverse transcription polymerase chain reaction
Sap-1 SRF accessory protein 1
SDS Sodium dodecyl sulfate
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SDS-PAGE Denaturant polyacrylamide gel electrophoresis
Siah1 Seven-in-absentia homologue
SOC Super optimal broth with catabolite repression
Sp-1 Specificity protein 1
SRE Serum response element
SRF Serum response factor 
SR101 Sulforhodamine 101 
TAD Trans-activation domain
TAE Tris-acetate-EDTA
TBP TATA binding protein
TBST Tris-buffered saline with Tween
TCF Ternary complex factor
TE Tris-EDTA
TEF-1 Transcription enhancer factor 1
TEMED N, N, N, N -Tetramethylethylendiamine 
TK Thymidine kinase
TPA 12-O-tetradecanoylphorbol-13-acetate
TPE TPA responsive element
Tris Tris(hydroxymethyl)-aminomethane 
TSC Tuberous sclerosis protein
URR Upstream regulatory region
VEGF Vascular endothelial growth factor
VHL Von-Hippel-Landau factor
v/v Volume percentage 
w/v Weight percentage
YY-1 Yin Yang 1
3.2  Material
3.2.1  Antibodies
Antibody Epitope Reference Use
Actin (Clone 4)
mouse monoclonal 
IgG
cat # 691001
Chicken gizzard actin MP Biomedical Inc., Eschwege Western 1:10000
Anti-Flag M2
mouse monoclonal 
IgG
cat # F3165
Flag peptide 
sequence
Sigma-Aldrich, 
Munich Western 1:5000
Anti-HA High Affinity
(Clone 3F10)
rat monoclonal IgG
cat # 1867423
HA peptide sequence
Roche 
Diagnostics, 
Mannheim
Western 1:1000
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Antibody Epitope Reference Use
Anti-mouse IgG HRP,
cat # W4021 
Mouse IgG heavy 
and light chain
Promega, 
Mannheim Western 1:10000
Anti-rabbit IgG HRP, 
cat # W401B
Rabbit IgG heavy 
and light chain
Promega, 
Mannheim Western 1:10000
Anti-rat IgG HRP Rat IgG heavy and light chain Dianova, Hamburg Western 1:10000
c-Fos 
rabbit polyclonal IgG
cat # 06-341
lot # 23255
amino acids 3-16 of 
human c-Fos
Upstate Cell 
Signaling, 
Hamburg 
Western 1:10000
Fra-1
rabbit polyclonal IgG
cat # sc-605X
lot #  H022
N-terminus of murine 
Fra-1
Santa Cruz 
Biotech, 
Heidelberg
Western 1:5000
HIF-1α (H-206)
cat # sc-10790 X
lot # L0905
amino acids 575-780 
mapping near the C-
terminus of human 
HIF-1α  
Santa Cruz 
Biotech, 
Heidelberg
Western 1:1500
HIF-2α
rabbit polyclonal IgG
cat # NB100-122
C-terminus of 
murine/human HIF-
2α
Novus Biologicals,
Cambridge (UK)
Western 1:2000
ChIP 1,5 µg  
Net antisera 2005 and 
2007 Human Net
Dr. Bohdan 
Wasylyk, IGBMC 
Illkirch, France
ChIP 1:50
Western 1:2000
Normal rabbit IgG, 
cat # sc-2027 Control IgG
Santa Cruz 
Biotech., 
Heidelberg
ChIP, 2 µg 
RNA polymerase II
rabbit polyclonal IgG
cat # ab5131-50
RNA polymerase II, 
CTD repeat 
YSPTSPS 
(phospho S5)
Abcam, 
Cambridge (UK) ChIP, 2 µg 
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3.2.2  PCR primers
Primers for promoter analysis
Gene Sequence Annealing temperature
PCR 
cycles
adh5
5'-CTGGAACGCACAACTTAGCAGCA-3'
5'-ATAGCAGCCTAGTCCCATGCC-3'
60 °C 35
gapdh
5'-CCCAACTTTCCCGCCTCTC-3'
5'-CAGCCGCCTGGTTCAACTG-3'
62°C 35
pai-1
5'-CAACCTCAGCCAGACAAGGT-3'
5'-ACCTCCATCAAAACGTGGAA-3'
55°C 35
Primers for cDNA analysis
Gene Sequence Annealing temperature
PCR 
cycles
gapdh
5'-ATATTGTTGCCATCAATGACC-3'
5'-GATGGCATGGACTGTGGTCATG-3'
65°C 20
HPV18 
E6/E7
5'-CGGAACTGAACACTTCACTGC-3'
5'-TGCGTCGTTGGAGTCTTTC-3'
65°C 18
pai-1
5'-CTCCGAGAATCCCACACAG-3'
5'-ACTTTGAATCCCATAGCATC-3'
60°C
(Buchwalter et al., 2005)
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β-Tub
VEGF
5'-TCTGTTCGCTCAGGTCCTTT-3'
5'-TTCATGATGCGATCAGGGTA-3'
5'-TCCTCACACCATTGAAACCA-3'
5'-CACCGATCAGGGAGAGAGAG-3'
59°C
53°C
35
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3.2.3  Oligos for EMSA
Oligo Sequence Reference
AP-1 consensus 5'-CGCTTGATGACTCAGCCGGAA-3' Collagenase gene
(Lee et al., 1987)
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3.2.4  Plasmids
Plasmid Insert Reference
pcDNA3.1 - Invitrogen, Karlsruhe
pcDNA3-HIF-1αP564A Human HIF-1α cDNA, substitution at P564 for increased stability
Ph.D. Olga Aprelikova, 
NIH, Bethesda (USA)
pcDNA-HIF-2αP531A Human HIF-1α cDNA, substitution at P531 for increased stability
Ph.D. Olga Aprelikova, 
NIH, Bethesda (USA)
pcDNA3-Flag-HIPK2 Human HIPK2 cDNA with N-terminal Flag-tag
Dr. Thomas Hofmann, 
DKFZ, Heidelberg
pcDNA-HA-Siah1 Human Siah1 cDNA with N-terminal HA-tag
Dr. Thomas Hofmann, 
DKFZ, Heidelberg
pcDNA-HA-Siah1C44S
Human Siah1, E3-ligase deficient 
mutant due to substitution at C44; 
encodes N-terminal HA-tag
Dr. Thomas Hofmann, 
DKFZ, Heidelberg
pEGFP Optimized variant of wild-type GFP cDNA
Clontech, Saint-Germain-
en-Laye (France)
pGL3(-1112)GAPDH 1112 bp of the human GAPDH promoter driving firefly luciferase
Ph.D. Shan Lu, University 
of Cincinnati, Cincinnati 
(USA)
pRL-TK
herpes simplex virus thymidine 
kinase (HSV-TK) promoter driving 
renilla luciferase
Promega GmbH, 
Mannheim
pSG5 - Agilent Technologies, Waldbronn
pTL2-Net Human Net cDNA
Dr. Bohadan Wasylyk, 
IGBMC, Strasbourg 
(France)
pCRII-TOPO-Tub 271 bp cDNA fragment of human β-Tubulin -
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3.2.5 Buffers and solutions
Agarose gel electrophoresis
DEPC water 0.1 %(v/v) DEPC
MOPS (20X) pH 7,0 400 mM MOPS
100 mM Sodium acetate
20 mM EDTA
pH 7.0 (DEPC water)
Store light protected
RNA loading buffer (2X) 50 % Formamide
2.2 M Formaldehyde
1 % (w/v) Ficoll (type 400)
0.02 % (w/v) Bromophenol blue
1X MOPS buffer pH 7.0
(DEPC water)
Store at -20 °C
TAE (50X) pH 7.8 2 M Tris Base
250 mM NaAc
50 mM EDTA pH 8.0
Bacteria culture
Ampicillin 100 mg/ml in water
Store at -20 °C
Kanamycin 50 mg/ml in water
Store at -20 °C
LB-ampicillin plates LB medium
2 % (w/v) Bacto-Agar
100 mg/l ampicillin
LB-kanamycin plates LB medium
2 % (w/v) Bacto-Agar
50 mg/l kanamycin
LB medium pH 7,2 10 % (w/v) NaCl
10 % (w/v) Bacto-Trypton
 5 % (w/v)  yeast extract
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SOC medium 2 % (w/v) Bacto-Trypton
0.5 % (w/v) yeast extract
10 mM NaCl
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4
20 mM Glucose
Calcium phosphate precipitation
CaCl2 2 M CaCl2
Sterile filter before use
HBS (2X) 280 mM NaCl
1.5 mM Na2HPO4
50 mM HEPES
Adjust to pH 7.05
Sterile filter before use
Cell culture
DMEM complete 500 ml DMEM
10 % (v/v) FCS
100 U/ml Penicillin
100 µg/ml Streptomycin
Freezing DMEM 60 % (v/v) DMEM
30 % (v/v) FCS
10 % (v/v) DMSO
Chromatin immunoprecipitation
Cell lysis buffer 85 mM KCl
5 mM HEPES pH 8.0
0.5 % (v/v) NP-40
Before use add protease and 
phosphatase inhibitors
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ChIP buffer 167 mM NaCl
16.7 mM Tris/HCl pH 8.0
1.2 mM EDTA pH 8.0
1.1 % (v/v) Triton X
0.01 % (v/v) SDS
Before use add protease and 
phosphatase inhibitors
Chloroform/Isoamylalcohol (24:1) 24 parts chloroform
1 part isoamylalcohol
Store light protected at 4 °C
Digestion and decrosslinking cocktail 320 mM NaCl
80 mM Tris/HCl pH 8
20 mM EDTA pH 8
80 µg/ml Proteinase K
Diluted in elution buffer
Need to be prepared freshly
Elution buffer 95 mM NaHCO3
1 % v/v SDS
Need to be prepared freshly
High salt buffer 500 mM NaCl
50 mM Tris/HCl pH 8.0
5 mM EDTA pH 8.0
0.5 % (v/v) NP-40
Lithium chloride buffer 250 mM LiCl
10 mM Tris/HCl pH 8.0
1 mM EDTA pH 8.0
0.5 % (v/v) NP-40
0.5 % (w/v) Sodium Desoxycholate
Low salt buffer 0.1 % (v/v) SDS
1 % (v/v) Triton X
20 mM Tris/HCl pH 8.0
150 mM NaCl
TE (1X) 10 mM Tris Base
1 mM EDTA pH 8.0
EMSA
TBE (10X) 0.9 M Tris Base
0.9 M Boric Acid
0.02 M EDTA pH 8.0
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TNE (1X) 100 mM Sodium chloride
Dissolved in 1X TE pH 8
Adjust to pH 7.4
Immunofluorescence
Mowiol 10 % 10 % Mowiol 4-88
25 % Glycerol
100 mM Tris/HCl pH 8.5
Paraformaldehyde 4 % 4 % Paraformaldehyde
Dissolved in PBS
Adjust to pH 7.2
Nuclear protein preparation
Buffer A 10 mM HEPES pH 7.9
10 mM KCl
0.1 mM EDTA pH 8.0
0.1 mM EGTA pH 7.9
Store at -20 °C
Before use add protease and 
phosphatase inhibitors
Buffer C 25 % (v/v) glycerol 99.5 %
20 mM HEPES pH 7.5
400 mM Sodium chloride
1 mM EDTA pH 7.9
Store at -20 °C
Before use add protease and 
phosphatase inhibitors
Protease and phosphatase inhibitors
Complete protease inhibitor 50X stock solution
Store at -20 °C
DTT 0.1 M stock solution
Store at -20 °C
MG-132 20 mM stock solution
Dissolve in DMSO
Store at -80 °C
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Sodium fluoride 500 mM NaF
Store at -20 °C
Sodium ortho-vanadate pH 10 10 mM NaVO4
Store at -20 °C
Western blot
APS 10 % (w/v) APS
Blocking Buffer (Western Blot) TBST
5 % (w/v) Milk powder
Store at 4 °C
Laemmli buffer (10X) 0.25 M Tris Base
1.9 M Glycine
1 % (w/v) SDS
SDS loading buffer (5X) 10 % (v/v) SDS
5 mg Bromophenol blue
12.5 % (v/v) 2-Mercaptoethanol
5 mM EDTA pH 8.0
50 % (v/v) Glycerol
300 mM Tris/HCl pH 6.8
Store at -20 °C
TBS (1X) 10 mM Tris /HCl pH 7.5
100 mM NaCl
TBST 1X TBS pH 7.6
0.1 % (v/v) Tween 20
Towbin (1X) 25 mM Tris Base
192 mM Glycine
0.1 % (w/v) SDS
15 % (v/v) Methanol
Whole cell protein extraction
RIPA buffer 10 mM Tris/HCl pH 8
150 mM NaCl
1 mM EDTA pH 8
1 % NP-40
0.1 % SDS
Before use add protease and 
phosphatase inhibitors
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3.2.6  Cell lines
Cell line Characteristics Reference
444
HeLa x fibroblast hybrids
Viral status: HPV 18
In  vivo  phenotype:  non-tumorigenic  after  s.c. 
injection into nu-/- mice
(Stanbridge, 1984)
CGL 3
HeLa x fibroblast hybrids (segregant of 444)
Viral status: HPV 18
In vivo phenotype: tumorigenic after s.c. injection 
into nu-/- mice
(Stanbridge, 1984)
HEK 293
Species: human, female, embryonic
Tissue: kidney
Viral status: partial sequence from Ad 5 genome
In vivo phenotype: tumorigenic after s.c. injection 
into nu-/- mice
(Graham et al., 
1977)
HeLa
Species: human, female, adult
Tissue: cervix, adenocarcinom
Viral status: HPV 18
In vivo phenotype: tumorigenic after s.c. injection 
into nu-/- mice
(Boshart et al., 1984;
Schwarz et al., 
1985)
IMR 90
Species: human, female, embryo
Tissue: lung, fibroblast
Viral status: negative
In  vivo  phenotype: non-tumorigenic  after  s.c. 
injection into nu-/- mice
(Nichols et al., 1977)
3.2.7  Chemicals and reagents
Acrylamide/bis-Acrylamide (29:1), 30 % Sigma-Aldrich, Munich 
Agarose Merck, Darmstadt
Ammonium persulfate Sigma-Aldrich, Munich
Ampicillin Roche Diagnostics, 
Mannheim
Bacto-Agar Invitrogen, Karlsruhe
Bacto-Tryptone BD Diagnostics, Heidelberg
Bovine Serum Albumin Sigma-Aldrich, Munich
Bradford-Reagent (Bio-Rad Protein Assay) Bio-Rad Laboratories, 
Munich 
Bromophenol Blue Sigma-Aldrich, Munich
Chloric acid Merck, Darmstadt 
Chloroform Merck, Darmstadt 
Complete Protease inhibitor, EDTA-free Roche, Mannheim
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Diethylpyrocarbonate (DEPC) Sigma-Aldrich, Munich 
Dihydroethidium 5 mM in DMSO Invitrogen, Karlsruhe
dNTP set Invitrogen, Karlsruhe
Dithiothreitol (DTT) Sigma-Aldrich, Munich
DNA 6X loading buffer Fermentas, St. Leon-Rot 
Dulbecco's modified Eagle's Medium (DMEM) Invitrogen, Karlsruhe 
ECL-Reagent PerkinElmer, Rodgau-
Jügesheim
EDTA Roche Diagnostics, 
Mannheim  
EGTA Sigma-Aldrich, Munich
Ethanol absolute Merck, Darmstadt 
Ethidiumbromide Fluka BioChemika, Buchs 
(CH)
Fetal calf serum Invitrogen, Karlsruhe 
Ficoll 400 Serva, Heidelberg
Formaldehyde Merck, Darmstadt 
Glycerol Merck, Darmstadt 
Glycine Sigma-Aldrich, Munich 
HEPES Gerbu, Gaiberg
Hoechst 33258 Sigma-Aldrich, Munich
Kanamycin Roche Diagnostics, 
Mannheim
Lithium chloride Fluka BioChemika, Buchs 
(CH)
Magnesium chloride Merck, Darmstadt 
2-Mercaptoethanol Sigma-Aldrich, Munich 
Methanol Merck, Darmstadt 
MG-132 Biomol, Hamburg
Milk powder Roth, Karlsruhe 
MOPS Gerbu, Gaiberg
Mowiol 4-88 Roth, Karlsruhe
Nonidet-P40 Roche Diagnostics, 
Mannheim 
PBS Invitrogen, Karlsruhe 
Penicillin 10000U/ml Invitrogen, Karlsruhe
Poly(dI-dC).poly(dI-dC) Amersham-Pharmacia, 
Freiburg
Potassium chloride Merck, Darmstadt 
Protein A Agarose Roche Diagnostics, 
Mannheim
Random primers p(dN)6 Boehringer, Mannheim
RNasin Plus RNase Inhibitor, 40 U/μl Promega, Mannheim
Roti-Phenol Roth, Karlsruhe 
Salmon Sperm Sigma-Aldrich, Munich
Sodium acetate Merck, Darmstadt 
Sodium chloride Merck, Darmstadt 
Sodium desoxycholate Merck, Darmstadt
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Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Munich
Sodium fluoride Merck, Darmstadt 
Sodium hydrogen carbonate Merck, Darmstadt
Sodium ortho-vanadate Sigma-Aldrich, Munich 
Streptomycin 10000 mg/ml Invitrogen, Karlsruhe
TEMED Invitrogen, Karlsruhe 
Trypsin/EDTA 0.25 % Invitrogen, Karlsruhe 
Triton X-100 Sigma-Aldrich, Munich 
Trizma-Base Sigma-Aldrich, Munich  
Trypan blue 0.5 % (w/v) in PBS Biochrom, Berlin
Tween 20 Sigma-Aldrich, Munich
3.2.8  Enzymes
DreamTaq Green DNA Master Mix (2X) Fermentas, St. Leon-Rot
GoTaq Green PCR Master Mix Promega, Mannheim
λ-Phosphatase 400000 U/ml NEB, Frankfurt a.M.
Proteinase K Roche Diagnostics, 
Mannheim
RQ1 RNAse-free DNAse Promega, Mannheim
SuperScript II (RNAse H (-) 200 U/µl) Invitrogen, Karlsruhe
T4 Polynucleotide kinase (10000U/ml) NEB, Frankfurt a.M.
3.2.9  Kits
CellTiter-Glo Luminescent Cell Viability Assay Promega, Mannheim
Dual Luciferase Reporter Assay System Promega, Mannheim
Effectene Transfection Reagent Qiagen Hilden
LightCycler FastStart DNA MasterPLUS SYBR Green I Roche, Mannheim
MiniPrep Kit Qiagen, Hilden
One Shot Top 10 Invitrogen, Karlsruhe
RNeasy Mini Kit Qiagen, Hilden
TOPO TA Cloning kit Invitrogen, Karlsruhe
3.2.10  Size Marker
Gene Ruler DNA-Ladder Mix Fermentas, St. Leon-Rot 
PageRuler Plus Prestained Protein Ladder Fermentas, St. Leon-Rot
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3.2.11  Other Consumables
Cell culture flasks (Corning) Sigma-Aldrich, 
Munich 
Cell culture plates Greiner Bio-One, Wemmel 
Cell scraper (Corning) Sigma-Aldrich, 
Munich
Coverslips Thermo-Scientific, 
Braunschweig
Eppendorf Tubes Eppendorf, Hamburg 
Films Hyperfilm ECL Amersham Bioscience, 
Freiburg  
Graduated pipettes Hirschmann, Eberstadt
Microscope slide Langenbrinck, Emmendingen
One Shot TOP10 Chemically Competent E. coli Invitrogen, Karlsruhe
Photometer plastic cuvette Cuvetteser, Nürtingen 
Polypropilene conical tubes (Falcon) BD, Heidelberg
PVDF-membranes (Immobilon P) Millipore, Eschborn 
Sterile Needles, Microlance 3 BD, Heidelberg
Transfer Membrane Hybond LFP PVDF GE Healthcare, Munich
Whatman 3 mm paper filter Schleicher and Schüll, 
Dassel 
3.2.12  Laboratory Equipment
Analytic scale AE 160 Mettler, Gießen 
Analytic scale basic Sartorius, Göttingen 
Autoradiography cassettes Kodak, Stuttgart
Bacteria shaker G25 Infors, Bottmingen (Schweiz)
BioPhotometer Eppendorf, Hamburg
Bioruptor Diagenode, Liège (B)
Bio-Trap electrophoresis chamber Renner, Dannstadt
Blotting chamber, semi-dry Hoefer Pharmacia Biotech, 
San Francisco (USA)
Centrifuge Biofuge, Varifuge RF Heraeus, Hanau 
Centrifuge 5415 R Eppendorf, Hamburg
Developer machine Curix 60 AGFA, Cologne 
DNA Engine DYAD and Tetrad 2 Cycler Bio-Rad, Munich
Fluoview FV1000 Olympus, Hamburg
Gel documentation system EASY 429 K Herolab, Wiesloch
Gel dryer model 583 Bio-Rad, Munich
Incubator C16 Labotect, Göttingen
Microscope CKX 41 Olympus, Hamburg
Microscope Leitz DM RBE Leica, Bensheim
Minifuge Heraeus, Hanau 
Mini-PROTEAN II (minigels western) BioRad, Munich 
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NanoDrop ND-1000 Nanodrop Technologies, 
Wilmington (USA)
Neubauer count chamber Bender and Hobein, 
Bruchsal  
pH-meter Calimatic 765 Knick, Egelsbach 
Pipette boy acu Hirschmann, Eberstadt 
Pipet-Lite Mettler-Toledo, Gießen 
Plate reader Mithras LB 940 Berthold Technologies, Bad 
Wildbad
Power supply PHERO-stab 500 Biotech-Fischer, Reiskirchen
Power supply Power Pac HC Bio-Rad, Munich
Polymax 2040 Heidolph, Schwabach
Scale 1216 MP Sartorius, Göttingen 
Sonifier 250 Branson/Heinemann, 
Schwäbisch Gmünd 
Sterile hood (BioGard Hood) Baker Company, Sandford 
Steri Cult 200 incubator Heraeus, Hanau
Thermomixer compact Eppendorf, Hamburg 
Trans-illuminator 254-366 nm Vetter,Wiesloch 
Vertical gel electrophoresis aparatus V15-17 Invitrogen, Darmstadt
Vortex Heidolf, Rust 
Water bath Julabo, Seelbach 
3.2.13  Analysis software
ImageJ 1.41o National Institute of Health (USA)
Mikrowin 2000 Mikrotek Laborsysteme, Overath
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3.3  Methods
3.3.1  Cell culture
Cell culture
All cells were cultured in complete DMEM (see buffer lists). When reaching 80 % to 
90 % confluence, cells were split. They were washed once with PBS and detached 
by incubating them 5-10 min in 0.25 % Trypsin/EDTA at room temperature. To stop 
the trypsinization, complete DMEM was added at a ratio of 5:1.  Finally, cells were 
diluted between 1/10 and 1/40, depending on  cell line and future experiments.
To  minimize  stress  for  the  cells,  all  used  reagents  were  adjusted  to  room 
temperature.
Cell counting
After trypsinization was stopped as described above, 15 µl of the cell  suspension 
were mixed 1:1 with Trypan blue and loaded into the Neubauer Chamber for cell 
counting. The final cell concentration (cells per milliliter) was calculated as described 
below:
cells ml = Ø counted cells
Øcounted squares
⋅dilution factor⋅104
Depending on the experimental approach, the following amount of cells were seeded:
Tab. 3.1: Amount of cells per cell culture dish 
96-well plate 24-well plate 6-well plate 20 cm2 dish 60 cm2 dish
444 1.5 • 104 8.0 • 104 3.0 • 105 4.0 • 105 2.5 • 106
CGL 3 2.5 • 104 1.6 • 105 8.0 • 105 9.0 • 105 5.0 • 106
HEK 293 - - - 4.0 • 105 -
HeLa 2.0 • 104 1.4 • 105 6.0 • 105 7.0 • 105 3.5 • 106
IMR 90 2.0 • 104 1.4 • 105 6.0 • 105 7.0 • 105 3.5 • 106
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Transient transfection using the calcium phosphate precipitation 
The calcium phosphate transfection is based on the reaction of sodium hydrogen 
phosphate and calcium chloride to christalline calcium phosphate (Graham and van 
der Eb, 1973). This precipitate binds the plasmid-DNA (pDNA) at its surface and the 
complex enters the cell via endocytosis.
The following protocol was used to transfect HEK 293 grown in 20 cm2 dishes. 8 µg 
pDNA were diluted in 0.2 M CaCl2 solution. HBS 2X  was added in a 1:1 ratio and the 
reaction  was  vortexed  vigorously  before  incubating  30 min  at  room temperature. 
Finally, the calcium phosphate crystals were broken up by intensive pipetting and the 
mix was transferred drop-wise to the cells. HEK 293 cells were harvested 2 days 
after transfection.
Transient transfection using the Effectene Transfection Reagent 
The Effectene Transfection Reagent (Qiagen is based on a non-liposomal two-step 
approach. First, the DNA is tightly condensed by the salt-containing Enhancer and 
later  on  coated  with  cationic  lipids  by  the  addition  of  the  Effectene  Transfection 
Reagent, allowing an efficient DNA transfer into eukaryotic cells.
The  Effectene  Transfection  Reagent  was  used  according  to  the  manufacturer's 
instructions. Cells grown in 20 cm2 were transfected with 1 µg pDNA diluted in 150 µl 
EC  buffer. To condense the DNA, 8 µl Enhancer were included and the reaction was 
incubated at room temperature for 5 min. Then, 25 µl Effectene Transfection Reagent 
were added, the mix was vortexed for 10 s and incubated for further 10 min at room 
temperature. Finally, the reaction was diluted in 1 ml DMEM and added drop-wise to 
the cells. Dependent on the scheduled experiment, the transfection mix was removed 
6-8 h after transfection.
Hypoxia
Generally, cells are grown at 21 % O2 and 5 % CO2 which is termed normoxia and 
used as control condition within this study. To monitor the cellular hypoxic reaction, 
cells were exposed to 1.5-2 % O2 in the incubator C16 (Labotect, Göttingen) one day 
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after  seeding.  Depending  on  the  experimental  approach,  the  hypoxia  treatment 
lasted from 6-24 hours. During that time, the incubator was always closed to prevent 
reoxygenation of the cells.
Cryoconservation and reactivation of eukaryotic cells
Subconfluent cells were trypsinized and the reaction was stopped as described in the 
“cell culture” section above. The cell suspension was pelleted at 1000 rpm for 2 min 
and  the  resulting  supernatant  was  discarded.  Next,  cells  were  resuspended  in 
freezing  DMEM (precooled to  4 °C ),  aliquoted into  cryotubes and slowly cooled 
down to -80 °C. For long-term storage, the frozen cells were transferred to liquid 
nitrogen.
To thaw cells, the cryosuspension was defrozen at room temperature and cells were 
washed once in DMEM with additives. Initially, the reactivated cells were cultured in a 
25 cm2 flask to allow cell-cell contact.
3.3.2  Preparation and analysis of proteins
Nuclear protein preparation
The  method  of  Schreiber  et  al.  was  used  to  prepare  nuclear  protein  extracts 
(Schreiber  et al., 1989). Phosphatases and proteases inhibitors were added to the 
buffers A and C as described in Tab. 3.2. Prior to nuclear protein preparation, the 
cells  grown  in  60 cm2 plates  were  subjected  to  hypoxia  (1.5-2 % O2)  or  control 
conditions for 24 h.
Tab. 3.2: Amount of cells per cell culture dish
Agent Function Final concentration
DTT Reducing agent 1 mM
Complete protease inhibitor Protease inhibitor 1X
MG-132 Proteasome inhibitor 1 µM
NaF Phosphatase inhibitor 1 mM
Sodium ortho-vanadate Phosphatase inhibitor 0.2 mM
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For  harvesting,  cells  were  washed  twice  with  ice-cold  PBS,  scraped  in  1.2 ml 
hypotonic  buffer  A and transferred  to  a  1.5 ml  Eppendorf  tube.  Following  15 min 
swelling on ice, 75 µl  of  the non-ionic detergent NP-40 were added, the samples 
were vortexed 10 s to complete the plasma membrane lysis and centrifuged 1 min at 
4 °C and 15500 g. The supernatant (cytoplasmic extract) was stored for subsequent 
RNA extraction and the pellet was resuspended in 100 µl ice-cold buffer C to extract 
the nuclear proteins. Then, the samples were incubated another 15 min on ice, being 
mixed every 2 min. After 5 min centrifugation, the supernatant containing the nuclear 
protein  extract  was  recovered  and  stored  at  -80 °C.  To  determine  the  protein 
concentration  of  the  extract,  a  Bradford  protein  assay  (Bradford,  1976)  was 
performed.
Whole cell protein preparation (RIPA) (Klotz et al., 1999)
For RIPA extract, cells were grown in 20 cm2 cell culture dishes and subjected to 
24 h  hypoxic  (1.5 % O2)  or  normoxic  conditions  prior  to  harvesting.  The  protein 
preparation was performed in ice-cold RIPA buffer supplemented with protease and 
phosphatase inhibitors as described in Tab. 3.2. 
To prepare whole cell protein extract, cells were washed twice with PBS, scraped in 
250 μl  RIPA buffer  and  transferred  to  1.5 ml  Eppendorf  tubes.  To  lyse  cellular 
membranes, cell suspensions were sonified twice for 10 s, with Sonifier 250 set to: 
timer “hold”,  duty cycle “50 %” and output control  “5”.  Subsequently,  suspensions 
were  incubated  20 min  on  ice  to  allow  complete  protein  extraction.  After  brief 
vortexing and 5 min centrifugation at 13,000 rpm, supernatants containing whole cell 
proteins  were  transferred  into  fresh  tubes  and  stored  at  -80 °C.   Protein 
concentrations were determined by Bradford protein assay.
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Bradford protein assay (Bradford, 1976)
The following reaction was prepared for every sample, including the calibration line:
• 800 µl Bio-Rad Protein Assay reagent
• 200 µl aqua dest. 
• 2 µl sample
For the standard curve, 1-12 µg BSA were measured. All samples were quantified at 
595 nm (the  absorbance  maximum of  the  protein  bound  “Bio-Rad  Protein  Assay 
reagent”), using the BioPhotometer. 800 µl “Bio-Rad Protein Assay reagent” and 200 
µl aqua dest. were set to zero point.
λ-Phosphatase treatment
To identify post-translational protein phosphorylation, cellular protein extracts were 
treated with λ-phosphatase (NEB). For this purpose, RIPA extracts were prepared in 
the absence of phosphatase inhibitors. 50 μg of protein extract were incubated with 
2000 U λ-phosphatase,  1X reaction buffer  and 1 mM MnCl2 at  30 °C for  30 min. 
Subsequently, 1X SDS-loading buffer was added, the reaction mix was cooked for 
10 min at 99 °C and subjected to SDS-PAGE.
SDS-PAGE (Laemmlie, 1970; Hames and Rickwood, 1990)
Prior to the separation of proteins by SDS-PAGE, they were denaturated by cooking 
10 min at 99 °C in 1X β-mercaptoethanol containing SDS-loading-buffer.
With SDS-polyacrylamide-gel electrophoresis (SDS-PAGE), proteins were separated 
according to  their  size.  The polyacrylamide gel  is  composed of a low-percentage 
stacking gel and a high-percentage running gel. The stacking gel concentrates the 
proteins  whereas  they are  separated  in  the  running  gel.  The negatively  charged 
detergent SDS in loading buffer and gel attaches to the proteins, neutralizes their 
positive charges and denaturates them. The scaffold of the gels, the polyacrylamide, 
builds  a  net-like  structure  separating  proteins  according  to  their  size.  Resolution 
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depends on the concentration of polyacrylamide. For an optimal separation, 10 % 
running gels for proteins of 40-70 kDa and 7 % running gels for larger proteins were 
used:
Tab. 3.3: Composition of polyacrylamide gels used for SDS-PAGE
Stacking gel 7 % running 
gel
10 % running 
gel
Tris/HCl, pH 6,8 0.126 M - -
Tris/HCl, pH 8,8 - 0.376 M 0.376 M
SDS 0.1 % (w/v) 0.1 % (w/v) 0.1 % (w/v)
Acrylamide/bis-Acrylamide (29:1) 3 % (w/v) 7 % (w/v) 10 % (w/v)
APS 0.05 % (w/v)  0.05 % (w/v) 0.05 % (w/v)
TEMED 0.12 % (w/v) 0.06 % (w/v) 0.06 % (w/v)
The SDS-PAGE was run at  15 mA until  the samples reached the separating gel. 
Then amperage was increased to 30 mA. The separation was stopped, when the 
blue coloured running front left the gel.
Western blot “semi-dry” (Gallagher et al., 1997)
Whatman Paper was soaked in Towbin buffer including 10 % methanol. To activate 
the PVDF-membrane (Immobilon P, Millipore or Hybond LFP, GE Healthcare), it was 
hydrated  in  100 %  methanol  for  1 min,  in  aqua  dest. for  5 min  and  finally,  the 
membrane was incubated further 15 min in Towbin buffer including 10 % methanol. 
After  setting  up  the  blotting  system,  the  transfer  proceeded  70 min  at  4 °C  and 
1.2 mA per cm2. 
Then the membrane was blocked in blocking solution (5 % milk powder in TBST) for 
at  least  one hour.  The first  antibody was diluted according to  the manufacturers’ 
recommendations in blocking solution and incubated with the membrane over night 
at  4 °C.  Having  washed  the  membrane  thrice  in  TBST for  15-20 min  each,  the 
second antibody (diluted as well in blocking solution) was added and incubated for 
1 h at room temperature. Finally, the washing was repeated and the ECL-reaction 
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was performed. In order to use the same membrane for reincubation with additional 
antibodies, it was “stripped” in 200 mM NaOH for 5 min and washed with water and 
TBST.
3.3.3  Preparation and analysis of nucleic acids
DNA electrophoresis (agarose gel electrophoresis)
DNA fragments like PCR products were visualized by agarose gel electrophoresis. 
Depending on the fragment size, 1-2 % agarose gels were prepared. The gels were 
run in 1X TAE buffer at constant voltage.
DNAse digest
Prior to RT-PCR, residual traces of DNA were removed from RNA preparations by 
RQ1 DNAse digest. For this purpose, 10 µg RNA were added to the reaction mix 
(20 U RNAsin, 2 U RQ1 DNAse, 10 mM Tris/HCl pH 7.5, 10 mM MgCl and 50 mM 
KCl) and incubated for 20 min at 37 °C. By the addition of 200 mM sodium acetate 
pH 4, the DNAse digestion was stopped.
Subsequently,  the  RNA was  purified  by the  RNeasy Mini  Kit.  Briefly,  the  sample 
volume was adjusted to 100 µl with DEPC-H2O, mixed with 350 µl RLT buffer, 250 µl 
100 % ethanol  and  3.5 µl  99 %  β-Mercaptoethanol  and  loaded  onto  the  column. 
Washing was performed according to the manufacturer's recommendations.
Quantification of nucleic acids
To quantify nucleic acids, 2 µl of each sample were subjected to spectrophotometrical 
analysis  by  the  NanoDrop  ND-1000  according  to  the  manufacturer's 
recommendations.
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RNA electrophoresis
In order to inactivate putative RNAses, all  used equipment like gel chambers and 
combs were  incubated  15 min  in  50 mM NaOH.  After  extensive  washing,  a  1 % 
agarose gel in 1X MOPS was prepared. 10 µl 1X RNA loading buffer were added to 
1 µg RNA and incubated 10 min at 65 °C. After chilling on ice for 3 min, samples 
were loaded to the gel.
RNA extraction using the RNeasy Mini Kit (Qiagen)
In order to obtain RNA and protein from the same samples, cytoplasmic extracts 
remaining from nuclear protein preparation was mixed with 0.44 M RLT buffer, 22 % 
Ethanol and 63.5 mM β-Mercaptoethanol. The sample was transferred sequentially to 
a  RNeasy  mini  column,  spinned  15 s  at  8000 g,  and  washed  according  to  the 
manufacturers recommendations. After drying the column, RNA was eluted in  30 µl 
DEPC-water by centrifugation. To monitor RNA integrity, a 1 % AGE-MOPS gel was 
run. RNA was stored at -80 °C.
Reverse transcription polymerase chain reaction (RT-PCR) 
To obtain cDNA, SuperScript II reverse transcriptase and random primers were used 
according to the manufacturer's instructions. Briefly, 1 µg of DNAse-purified RNA and 
15 mM random primers were incubated 10 min at 70 °C and immediately transferred 
onto ice.  For  primer annealing,  1X reverse transcription (RT) buffer,  10 mM DTT, 
500 mM dNTPs were added and incubated at 25 °C for 10 min. After including 100 U 
SuperScript II,  synthesis of the first  cDNA strand was carried out 50 min at 42 °C 
followed by 15 min at 70 °C. cDNA was stored at -20 °C.
Semi-quantitative PCR
PCR was performed in a final  volume of 25 µl.  For ChIP analysis,  GoTaq Green 
Master Mix (Promega) was used. The final concentrations were: 1X Promega  Go Taq 
Green Master Mix, 4 % DMSO and 400 nM of each primer.  Two different amounts of 
template DNA (1 µl and 3 µl) were used, in order to monitor the quantitative range of 
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the PCR. 
For amplification of cDNA,  DreamTaq Green Master Mix (Fermentas) was applied: 
The relative amounts were 1X DreamTaq Green Master Mix, 400 nM of each primer 
and 1 µl cDNA.
For number of cycles and annealing temperatures of the specific primers see chapter 
3.2.2. The following standard PCR program was used:
Tab. 3.4: Semi-quantitative PCR program
PCR program Temperature Continuance
Denaturation 95 °C 5 min
 Cycles (gene specific) Denaturation 95 °C 30 s
Annealing Primer specific 30 s
Elongation 72 °C 30 s
Final elongation 72 °C 10 min
Cooling 4 °C forever
PCR products were analyzed in 2 % agarose gels. 
Quantitative PCR (qPCR)
The relative amount of GAPDH cDNA was determined by quantitative RT-PCR using 
LightCycler FastStart DNA MasterPLUS SYBR Green I according to the manufacturer’s 
instructions.  The cyanine dye SYBR Green I  forms complexes with  dsDNA which 
absorb blue light at 494 nm and emit green light at 521 nm. The quantification of the 
PCR  product  is  enabled  by  the  linear  correlation  of  fluorescence  intensity  and 
amount of DNA. As a reference, 5 distinct concentrations of pCLII-TOPO-Tub (7.5 ng, 
750 pg,  75 pg,  7.5 pg,  0.75 pg)  were  included  in  every  qPCR  run,  enabling  the 
generation of a calibration line with a minimal  error of  <0.07. GAPDH cDNA was 
relatively quantified by first subtracting the background (sample with water instead of 
cDNA) and then by normalizing against Tubulin to correct for differences concerning 
quality  and  amount  of  cDNA.  Finally,  values  were  displayed  as  percentages 
compared to normoxia set to 100 %. PCRs were performed in 10 μl total volume with 
1X LightCycler FastStart DNA MasterPLUS SYBR Green I, 2 μM Primer and 1 μl cDNA. 
qPCRs were run following this program:
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Tab. 3.5: qPCR program
qPCR program Temperature Hold time Acquisition
Denaturation 95 °C 10 min -
50 cycles
Denaturation 95 °C 10 s -
Amplification 59 °C 5 s -
Elongation 72 °C 20 s single
Melting Curve
95 °C 0 s -
50 °C-95 °C 15 s -
95 °C 0 s continuous
Cooling 40 °C 30 s -
Cloning of PCR products
To  create  a  quantitative  reference  for  qPCR analysis,  a  271 bp  fragment  of  the 
human β-Tubulin cDNA was cloned into the pCLII-TOPO vector. Initially, the fragment 
was  amplified  from  2 μg  444  cDNA  using  the  DreamTaq  Green  Master  Mix 
(Fermentas)  according  to  the  manufacturer's  recommendations  and  the  β-Tub 
primers described in 3.2.2. 4 μl of the PCR reaction were mixed with 1 μl TOPO TA 
vector and 1 μl salt solution derived from the TOPO TA cloning kit (Invitrogen). To 
allow the ligation of TOPO TA vector and PCR product, the reaction was incubated 
for  30 min at room temperature.  Subsequently,  chemical  competent TOP10  E.coli 
were transformed.
Propagation of pDNA by competent TOP10 E.coli
To  propagate  the  vectors  needed  for  transfection  of  eukaryotic  cells,  chemically 
competent  TOP10  E.coli  (Invitrogen)  were  transformed  according  to  the 
manufacturer's recommendations. Briefly, TOP10 bacteria were slowly thawn on ice. 
After  adding  the  vector  solution,  bacteria  were  additionally  incubated  on  ice  for 
30 min, heat shocked at 42 °C for 30 s and immediately returned to ice. 250 µl of 
SOC medium were added, bacteria were shaken for 1 h at 37 °C and subsequently 
propagated  on  antibiotica  containing  LB dishes  over  night.  Single  colonies  were 
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picked and liquid cultures were inoculated. After  24 h incubation at 37 °C, plasmid 
DNA was isolated using the MiniPrep kit or the MaxiPrep kit (Qiagen) according to 
the manufacturers' instructions. 
Sequencing of plasmids
All plasmids used in this study were sequenced prior to their first usage by GATC 
Biotech  AG  (Konstanz)  to  ensure  absence  of  point  mutations  and  correct  open 
reading frames.
3.3.4  Protein-DNA interaction
Chromatin Immunoprecipitation (ChIP) 
   (Weinmann et al., 2001)
Formaldehyde crosslinking and cell harvesting: Cells grown in 60 cm2 dishes were 
subjected to 2 % O2 or control conditions for 24 h. For harvesting, the growth medium 
was exchanged to DMEM without additives, Formaldehyde was added to 1 % final 
concentration and the cells were cross-linked at room temperature for 10 min. The 
reaction was stopped with 0.125 M glycine. After 5 min incubation, the cells were 
washed twice with PBS, trypsinized for 20 min at 37 °C, scraped and transferred to 
an Eppendorf tube. Cell pellets were washed once with PBS. 
Estimation of chromatin amount: The cell pellets were resuspended in 1 ml Cell Lysis 
Buffer,  incubated  on  ice  for  20 min  and  vortexed  1 min  to  break  the  cellular 
membranes.  To  estimate  the  amount  of  chromatin,  nuclei  were  counted  in  the 
Neubauer chamber: 
107 nuclei ≈ 150 µg chromatin
Chromatin shearing by sonification: The nuclei were pelleted by centrifugation (1 min 
at  15500 g,  4 °C)  and  resuspended  in  500 µl ChIP  buffer.  The  suspension  was 
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passed 10 times through a Microlance needle to break up the nuclei and incubated at  
least 15 min on ice. After 10 min sonification (constant output, 10 % duty) in an ice 
bath, nuclear debris was removed by centrifuging 10 min at 4 °C and 15500 g. 
Analysis of chromatin shearing: 2 µg of sheared chromatin were decrosslinked over 
night   in  0.3  M  sodium  chloride,  shaking  at  65 °C.  After  1:1  phenol-chloroform 
extraction, DNA was purified by ethanol precipitation (100 % ethanol,  3 M sodium 
acetate and 1 µg glycogen). Samples were resuspended in 20 µl water and analyzed 
in an 1.5 % agarose gel.
Preclearing and ChIP:  For  preclearing,  25 µg sonified chromatin  were mixed with 
40 µg salmon sperm and 40 µl of blocked protein A agarose beads (50 % slurry) and 
rocked for  2 h at  4 °C.  Agarose beads were  removed by centrifugation (2 min at 
15500 g, 4 °C). Subsequently 2 µg of unspecific control antibody or RNA polymerase 
II  antibody were  included.  After  over  night  rotation  at  4 °C,  the  antigen-antibody 
complex was pulled  down by 40 µl  protein  A agarose beads during  3 h  at  room 
temperature. 
Complexes were washed using 500 µl high salt buffer. After 5 min incubation, the 
complexes were pelleted by centrifugation (2 min at 4 °C,  15500 g).  The washing 
procedure was repeated twice with low salt buffer, twice with lithium chloride buffer 
and twice with TE buffer. 
To  elute  the  formaldehyde  cross-linked  protein-DNA complexes  from  beads  and 
antibodies,  the  mixture  was  rocked  40  min  in  50 µl  elution  buffer  at  room 
temperature.
For the second IP, the eluate was transfered to a new Eppendorf tube and completed 
to 500 µl using ChIP buffer. 2 µg of unspecific control antibody were added to the 
samples precipitated with control antibody. To samples precipitated with RNA pol II 
antibody, Net antiserum 2007 (concentration 1:50) or 1.5 µg of HIF-2α antibody were 
included.  Precipitation  was  carried  out  over  night  at  4 °C  and  antigen-antibody 
complexes were  pulled  down and washed as  described above.  For  final  elution, 
250 µl elution buffer were added and the protein-DNA complexes were eluted 20 min 
at room temperature. 
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Decrosslinking and purification of DNA: To remove remaining proteins and to release 
the formaldehyde cross-linking, a digestion and decrosslinking cocktail was included 
in a 1:1 ratio to the DNA-protein containing supernatant. From here on, the input 
chromatin sample was included as a positive control for PCR and processed in the 
same way as the IP chromatin. During the following two hours, the proteins were 
digested by Proteinase K at 37 °C. Then, temperature was increased to 65 °C which 
inactivated the Proteinase K and DNA complexes were decrosslinked over  night. 
Finally,  the  DNA  was  purified  by  phenol  :  chloroform  extraction  and  ethanol 
precipitated using 3 M sodium acetate and 1 µg glycogen as a carrier. DNA pellets 
were resuspended in 60 µl water. Purified ChIP DNA was stored at -20 °C.
Electrophoresis Mobility Shift Assay (EMSA)
The interaction of DNA and DNA-binding proteins like transcription factors can be 
determined by electrophoresis mobility shift assay (EMSA). This technique is based 
on the different migration properties of protein-DNA complexes and DNA alone in a 
non-denaturizing  polyacrylamide  gel:  Transcription  factor  binding  to  a  double-
stranded oligonucleotide leads to a retarded migration due to an increased size of the 
protein-DNA complex. In order to identify specific proteins involved in the complex 
formation,  antibodies  can  be  applied  prior  to  PAGE  which  leads  to  a  further 
retardation of the protein-DNA-antibody complex. 
Oligonucleotide strands (sense and anti-sense)  were annealed in  TNE in  a PCR 
machine using the following PCR program: 85 °C for 10 min followed by a sequential 
temperature  decrease  of  0.5 °C  every  30 s.  200 ng  of  annealed  oligonucleotides 
were end-labeled with 3,000 Ci/mmol [γ-32P] dATP by T4 polynucleotide kinase at 
37 °C for 30 min. To remove non-labeled oligonucleotides, the mix was subjected to 
PAGE: 15 % polyacrylamide/1X TBE-gel electrophoresis at 200 V for 90 min. Finally, 
the radioactively labeled oligonucleotides were excised from the gel and extracted in 
TNE. 
The EMSA was performed in a 20 μl reaction volume containing 1X EMSA binding 
buffer  suplemented  with  phosphatase  and  protease  inhibitors,  2 μg 
poly(dI/dC).poly(dI/dC),  2 μg  nuclear  protein  extract  and  10,000 cpm  of  5’  end-
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labeled  probe.  The  reaction  was  incubated  for  30 min  at  room  temperature.  To 
confirm the specificity of the complex formation, the unlabeled oligonucleotide probe 
was included in molar excess to compete with the labeled probe for binding to the 
protein complexes. For supershift analysis, 2 μg of the specific antibody were added 
and  the  reaction  mix  was  further  incubated  at  4 °C  for  1 h.  Finally,  the  different 
complexes were separated in a 5.5 % non-denaturating polyacrylamide/1X TBE-gel 
which was subsequently dried on a Whatmann 3MM filter paper and exposed to X-
ray films at -80 °C for hours to days depending on the intensity of the signal.
3.3.5  Reporter assays
ATP assay (CellTiter-Glo Luminescent Cell Viability Assay, Promega)
The  ATP assay  can  be  used  to  determine  cellular  survival  as  there  is  a  direct 
relationship between ATP content and cell viability. To quantify the ATP, the applied 
CellTiter-Glo cell viability assay takes advantage of a firefly luciferase based system. 
The firefly luciferase requires the ATP to catalyze the oxidative carboxylation of the 
substrate luciferin. The product of this reaction emits light at a wavelength of 537 nm 
which can be quantified.
The  CellTiter-Glo  Luminescent  Cell  Viability  Assay  was  used  according  to  the 
manufacturer's  recommendations  with  slight  modifications.  Cells  were  grown  in 
opaque 96-well plates, in triplicate for each experiment. The CellTiter-Glo assay was 
carried out at 37 °C. After 24 h hypoxia (1.5 % O2) or normoxia, 80 µl CellTiter-Glo 
reagent  were  added  to  each  well  and  the  plate  was  rocked  for  2 min  to  allow 
complete permeabilization of the cellular membrane. To stabilize the luciferin signal, 
the  reaction  was  incubated  for  further  10 min.  Finally,  the  light  emission  was 
quantified by the Mithras LB 940 plate reader using the Mikrowin2000 software.
Graphics depict the percental change of the ATP level after 6 h hypoxia compared to 
normoxia.
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GAPDH reporter assay (Dual Luciferase Reporter Assay System, 
Promega)
To  monitor  the  transcriptional  regulation  of  the  glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH)  gene,  the  Dual  Luciferase  Reporter  Assay  System 
(Promega)  was  applied.  Here,  the  activity  of  a  GAPDH  promoter  driven  firefly-
luciferase and a HSV-Thymidinkinase driven  renilla-luciferase were quantified one 
after the other to exclude variations caused by different transfection efficiencies.
444 and CGL 3 grown in 20 cm2 dishes were transfected with the reporter pGL3-
GAPDH(-1112),  the  normalization  vector  pRL-TK,  a  combination  of  vectors 
expressing  HIF-1α,  HIF-2α,  Net,  Siah1  or  Siah1C44S and  pEGFP.  6 h  after 
transfection,  cells  were  split  1:3  in  6-well  plates.  To  monitor  overall  transfection 
efficiency by EGFP expression, 1:15 of the transfected cells were grown on cover 
slides and later on analyzed by immunofluorescence.  When indicated,  cells were 
subjected to 2 % O2 or control conditions for 24 h the next day.
To prepare the cellular extract for the reporter gene analysis, cells were washed twice 
with ice-cold PBS and scraped in 1X Passive Lysis Buffer. After brief vortexing, cell  
debris was removed by centrifugation. The extract was stored at -80 °C.
For read-out of the Luciferase signal, 10 μl of each extract were loaded onto a 96-
well  plate.  LARII  and  Stop&Glow  buffers  were  prepared  according  to  the 
manufacturer’s instructions. The signal was quantified in the Mithras LB 940 plate 
reader, using the following program:  injection of 50 μl LARII, 2 s incubation, 10 s 
reading,  injection  of  50 μl  Stop&Glow,  2 s  incubation  and  10 s  reading.  firefly-
luciferase readings were normalized to  Renilla-luciferase readings. Graphics show 
the fold-induction of the GAPDH reporter compared to the induction of the GAPDH 
reporter observed in a control transfection (without transcription factors) set to 100 %.
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3.3.6  Immunofluorescence
ROS detection by dihydroethidium (DHE) (Bucana et al., 1986; Carter et 
al., 1994)
Intracellular ROS can be visualized by oxidation of DHE.  When excited, the resulting 
product emits light at a broad spectrum from 560-610 nm. For ROS detection, 2.5 µM 
DHE, also known as hydroethidine, were added to the cells 30 min prior to fixation. 
Until  harvesting,  cells  were  subjected  again  to  hypoxic  or  normoxic  conditions, 
depending on the previous treatment.
Fixation and Hoechst staining
Cells  grown  on  cover  slides  were  rinsed  with  PBS  and  fixed  in  4 % 
Paraformaldehyde  for  20 min  at  room temperature.  After  washing  5 min  in  PBS, 
nuclei  were  stained  for  20 min  at  room temperature  with  Hoechst  33258  diluted 
1:10000 in PBS. Finally, samples were washed three times in PBS and one time in 
water, rinsed in 100 % Ethanol, mounted on glass slides in 10 % mowiol and dried 
over night in the dark.
Microscopic analysis
Previously stained and fixed cells were analyzed for GFP expression to ensure equal 
transfection efficiency,  Hoechst  33258 staining of  the nuclei  or  DHE oxidation by 
reactive oxygen species (ROS).
GFP was first isolated from the jelly fish  Aequorea victoria. Since then, it has been 
genetically  modified  to  obtain  a  better  thermostability  and  improve  the  handling. 
When excited by blue light, it has a major emission peak at 509 nm. To distinguish 
between the total  number of cells and the number of transfected cells, the nuclei 
were stained with Hoechst 33258. This dye binds to DNA and emits cyan light when 
stimulated at 350 nm (ultraviolet spectrum). For GFP and Hoechst 33258 analysis, 
the microscope Leitz DM RBE (Leica) was used.
To monitor  intracellular  ROS levels  under  normoxic  and hypoxic  conditions,  cells 
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were  stained  with  DHE.  When  oxidized,  the  product  can  be  excited  at  490 nm 
wavelength and emits a broad spectrum between 560-610 nm. Here, emission was 
recorded at 605 nm. For ROS detection, the Microscope CKX 41 was used.
3.3.7  Cell cycle analysis
Fluorescence activated cell sorting (FACS)
Cells grown in 6-well dishes were trypsinized, washed twice with PBS and fixed in 
70 %  ethanol  at  least  over  night.  For  FACS  analysis,  the  fixation  solution  was 
removed by centrifugation and the cell pellet was resuspended in the DNA staining 
solution containing DAPI to stain the DNA and sulforhodamine 101 (SR101) to stain 
the  protein  following  a  protocol  published  by  Stoehr  and  Goerttler  in  1979. 
Processing, cell cycle analysis and quantification of apoptotic cells was performed 
according to Dean and Jett, 1974. 
4.  Results
4.1  Net and HIF-2α synergistically regulate GAPDH transcription
4.1.1  Hypoxic GAPDH regulation changes in cervical cancer cells
Hypoxia is known to regulate GAPDH transcription in a cell  type specific manner 
(Graven  et al.,  2003). GAPDH expression increases upon hypoxia in multiple cell 
lines  which  is  mediated  by  two  hypoxia  response  elements  within  its  promoter 
(Graven et al., 1999; Lu et al., 2002). 
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Fig. 4.1: Hypoxia exerts a cell type dependent effect on GAPDH expression. IMR 90, 444, 
CGL 3 and HeLa were subjected to hypoxia (1.5 % O2) (“H”) or normoxia (“N”) for 24 h. RNA 
was extracted, purified from DNA and reverse transcribed. The resulting cDNA was analyzed by 
semi-quantitative PCR for PAI-1, GAPDH and Tubulin (A). In addition, GAPDH expression was 
monitored by qPCR (B). The GAPDH expression data was normalized to the control Tubulin. 
Error bars represent the standard deviation between three independent experiments. The table 
in the lower part of (B) depicts the percentaged changes of GAPDH expression upon hypoxia. 
To monitor the hypoxic response of GAPDH in the fibroblasts IMR 90, the HeLa x 
fibroblast hybrids 444, their tumorigenic segregants CGL 3 and the cervical cancer 
cell  line  HeLa,  cells  were  subjected  to  1.5 %  O2 for  24 h.  Subsequently,  the 
expression of GAPDH was monitored by semi-quantitative and quantitative PCR.
According to  Fig.  4.1 A  and B,  GAPDH mRNA levels  are differentially regulated 
under  hypoxia  in  non-tumorigenic  and  tumorigenic  cell  lines.  Whereas  the  non-
tumorigenic  IMR 90  and  444  upregulate  their  GAPDH  expression  upon  oxygen 
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deprivation, the tumorigenic cell lines HeLa and CGL 3 display either no significant 
change of GAPDH mRNA levels or even a decrease (Fig. 4.1 B), respectively. This 
tendency is conserved in three independent experiments. 
To exclude genome wide transcriptional variations or differences in concentration and 
quality of the cDNA, the expression of  β-tubulin and PAI-1 were analyzed (Fig. 4.1 
A). As a loading control and a gene, which is not influenced by hypoxia, β-tubulin is 
equally expressed in all tested samples. In contrast, PAI-1 is known to be a hypoxia 
responsive  gene  (Liao  et  al.,  2007).  As  shown  in  Fig.  4.1  A,  its  expression  is 
upregulated under hypoxia in all tested cell lines – which emphasizes the cell type 
specific effect of GAPDH regulation depicted in Fig. 4.1 B.
In conclusion, GAPDH expression is regulated in a cell type dependent manner. The 
present data suggests a connection of tumorgenicity and an altered hypoxic GAPDH 
regulation. 
4.1.2  Net and HIF-2α bind to the GAPDH promoter
Hypoxic changes of GAPDH mRNA levels could be regulated on transcriptional level.  
Previous  in silico analysis of the GAPDH promoter suggests a Net binding site in 
close proximity to a previously reported HRE which could be bound by HIF-2α (Fig. 
Fig. 4.2: GAPDH promoter model.  Displayed are previously identified  cis-regulatory elements for 
insulin response factors (IRF), HIF-1, HIF-2 and TATA binding protein (TBP) located within 500 bp 
upstream of the GAPDH transcriptional start site (Nasrin et al., 1990). The indicated Net binding site  
was predicted by in silico analysis.
Both transcription factors play an important role in the hypoxic response (Gross et al., 
2008; Wiesener  et al., 1998). Moreover, the location of their response elements at 
the GAPDH promoter (Fig. 4.2) would enable a synergistic  trans-activating effect, 
which was previously described for Net related proteins and  HIF-2α (Elvert  et al., 
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2003; Aprelikova et al., 2006). However, the expression of Net and HIF-2α is cell type 
dependent. Therefore, the mRNA and protein levels of both genes were analyzed in 
Fig. 4.3: Net and HIF expression under normoxic and hypoxic conditions 444 and 
CGL 3  were  cultured  24 h  under  normoxia  or  2 % O2. Subsequently,  nuclear  protein 
extract  and RNA were prepared.  (A)  RNA was  purified from DNA contamination and 
reverse transcribed. The expression of VEGF, Net, HIF-1α, HIF-2α and β-Tubulin was 
analyzed by semi-quantitative PCR. (B) 25 µg nuclear protein extract were subjected to 
Western Blot. The  protein levels of  Net, HIF-1α, HIF-2α and RNA polymerase II were 
determined.
According to Fig. 4.3 A and B, 444 and CGL 3 differ essentially in their Net mRNA 
and protein levels: 444 expresses higher Net levels compared to CGL 3, which is 
shown on both mRNA and protein level and indicates different transcriptional activity 
of the Net gene in both cell lines. The low Net protein levels in CGL 3 are further 
reduced upon hypoxia, while they remain unchanged in 444.
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Concerning HIF-1α and HIF-2α, the protein levels do not correlate with the amount of 
RNA detected. While the RNA levels of HIF-1α are slightly reduced upon hypoxia in 
both cell lines, HIF-2α remains unchanged in CGL 3 or it is slightly upregulated in 
444 (Fig 4.3 A). In contrast, hypoxia has a tremendous effect on HIF protein levels: 
while  HIF-1α and  HIF-2α are  almost  undetectable  under  normoxia,  they strongly 
accumulate upon hypoxia (Fig 4.3 B).  The hypoxic stabilization of HIF proteins is 
considered to be a major event in the cellular hypoxic response and was described 
previously (Wang and Semenza 1993; Wiesener  et al.,  1998). Comparing the cell 
lines 444 and CGL 3, they slightly differ in their expression levels for both HIF factors. 
While 444 depict more HIF-1α than CGL 3, this ratio changes in the case of HIF-2α 
(Fig 4.3 B).
Vascular endothelial  growth factor (VEGF) expression was analyzed as a hypoxic 
control  gene.  VEGF  is  known  to  be  transcriptionally  upregulated  under  hypoxia 
(Shweiki  et al., 1992), which is depicted as well in  Fig. 4.3 A. CGL 3 constitutively 
express  VEGF under normoxia, which is a well-studied feature of tumorigenic cells 
(Kodama et al., 1999).
In conclusion, both Net and HIF-2α are expressed in 444 and CGL 3. 444 shows high 
Net RNA and protein levels, while Net expression in CGL 3 is close to the detection 
limit. HIFs proteins massively accumulate under hypoxia, which is an expected, post-
translational  event.  There  are  only  minor  variations  of  HIF  RNA levels.  HIF-2α 
expression is slightly higher in CGL 3, while there is more  HIF-1α in 444.
4.1.3  Net and HIF-2α bind to the GAPDH promoter
As  outlined  above,  Net  and  HIF-2α  may  be  involved  in  GAPDH  transcriptional 
regulation.  The  location  of  their  in  silico predicted  binding  sites  at  the  GAPDH 
promoter  may  enable  a  common  trans-activating  effect  which  was  previously 
reported for Net related proteins and HIF-2α. Considering their important role in the 
hypoxic response, an impact of Net and HIF-2α on the hypoxic regulation of GAPDH 
is likely. Initially, the promoter binding of both factors was analyzed under normoxic 
and hypoxic conditions by chromatin immunoprecipitation.
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Fig. 4.4: ChIP showing differential binding of Net and HIF-2α at the GAPDH promoter. The 
displayed ChIP involves two immunoprecipitation steps: A first one using an antibody directed 
against active RNA Polymerase II to select for actively transcribed genes. And the second one 
to specifically determine the binding of Net and HIF-2α. Following elution and purification, the 
resulting DNA was analyzed by semi-quantitative PCR. Depicted are the results for the GAPDH,  
PAI-1 and ADH 5 promoter (A). Net and HIF-2α indicate the specific antibodies, IgG stands for 
the unspecific IP control, Input represents non-IP chromatin. Prior to ChIP, 444 and CGL 3 were 
grown under normoxia (“N”) or 2 % O2 (“H”) for 24 h. (B) The semi-quantitative ChIP results for 
GAPDH and PAI-1 shown in (A) were quantified by the ImageJ software. IgG, HIF-2α and Net IP 
values were normalized to the non-IP chromatin referred to as “Input” in (A).
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These results indicate, that both Net and HIF-2α bind to the promoter of GAPDH in 
444 and CGL 3 (Fig. 4.4 A and B). However, their binding seems to be differentially 
regulated  under  hypoxia:  While  the  binding  of  Net  and  HIF-2α  at  the  GAPDH 
promoter is rather low in 444 under normoxic conditions, it increases upon hypoxic  
treatment (Fig. 4.4 B).  In contrast,  the promoter binding of  both factors in CGL 3 
does not change upon oxygen deprivation. The presence of HIF-2α at the GAPDH 
promoter under normoxic conditions does not correlate with the overall protein levels 
(Fig. 4.3): Although its low expression levels under normoxia, it binds to the GAPDH 
promoter  in  both  444  and  CGL 3  in  significant  amounts. Similar,  the  nuclear 
accumulation of HIF protein upon hypoxia is not reflected by its GAPDH promoter 
binding.
As a positive control, the promoter of plasminogen activator inhibitor 1 (PAI-1) was 
analyzed. This gene is known to be regulated by Net (Buchwalter et al., 2005) and 
HIF-2α (Liao  et al., 2007). Here, the promoter binding of Net and HIF-2α shows a 
similar pattern compared to GAPDH: The binding of both transcription factors to the 
PAI-1 promoter in 444 is increased under hypoxia, with the relative increase of Net  
being higher than the relative increase of HIF-2α (Fig. 4.4 B). In CGL 3, the presence 
of Net and HIF-2α at the PAI-1 promoter shows the opposite: Hypoxic HIF-2α levels 
remain unchanged while the binding of Net is diminished. 
The promoter of alcohol dehydrogenase 5 (ADH5) was included as a negative control 
for ChIP. As a housekeeping gene constitutively transcribed by RNA polymerase II 
(Hur and Edenberg, 1992), but neither regulated by Net nor by HIF-2α it enabled the 
specificity control for the second IP step.
Summing up, it could be shown that Net and HIF-2α bind to the promoters of GAPDH 
and PAI-1 under normoxic and hypoxic conditions. However, Net and HIF-2α binding 
seems to be differentially regulated in 444 and CGL 3 under hypoxic conditions.
4.1.4  Net and HIF-2α synergistically act on a GAPDH reporter
To determine the function of Net and  HIF-2α in GAPDH transcriptional regulation, 
luciferase assays were performed. As depicted in Fig. 4.5, the effect of different co-
transfected transcription factors on a GAPDH-luciferase-reporter harboring 1112 bp 
of the endogenous GAPDH promoter was monitored. 
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Fig. 4.5: Net and HIF-2α synergistically activate the GAPDH reporter.  To monitor the effect of Net, 
HIF-1α,  and  HIF-2α  on  a  GAPDH-promoter  driven  firefly-luciferase  reporter,  the  mentioned 
transcription factors  either  alone or  in  the indicated combinations were co-transfected in  444 and 
CGL 3 cells (A) and subjected to 24 h hypoxia (B). The displayed values represent relative changes in 
the GAPDH-reporter activity normalized to normoxic control samples and a co-transfected TK-renilla-
luciferase reporter, which is not regulated by Net or HIFs. “N” and “H” indicate normoxia and 2 % O2, 
respectively. Error bars represent variations within three independent experiments. A GFP expression 
plasmid was included (A) to rule out potential variations in the transfection efficiency. Presented are 
merged pictures of nuclear Hoechst 33258 staining and GFP.
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Only  the  co-transfection  of  Net  and  HIF-2α  induced  a  significant  synergistic 
upregulation of the GAPDH-luciferase-reporter in 444 cells (Fig. 4.5 A). This effect is 
further boosted under hypoxic conditions (Fig. 4.5 B). Neither Net, HIF-1α or HIF-2α 
alone nor a combination of Net and HIF-1α was able to induce the reporter to this 
extent. Interestingly, the synergism could be only demonstrated in non-tumorigenic 
444  cells.  In  tumorigenic  CGL 3,  the  co-transfection  of  HIF-2α  alone  or  in 
combination with Net induced a less than 5-fold induction of the GAPDH-reporter in 
comparison to a 18-fold induction in 444. Hypoxia does not significantly induce the 
GAPDH reporter  in  CGL 3  cells,  too  (Fig  4.5  B).  This  data  indicates  a  different 
regulation of GAPDH transcription upon hypoxia in both cell lines.
An unintended reason for the different regulation of the GAPDH reporter in 444 and 
CGL 3 could be differences in the transfection efficiency. To exclude this possibility, a 
GFP expressing plasmid was co-transfected and the expression of GFP was later-on 
monitored  by fluorescence at  509 nm (Fig.  4.5  A).  The results  indicate,  that  the 
inability of Net and HIF-2α to activate the GAPDH-reporter in CGL 3 is not due to 
different transfection efficiencies.
Overall,  Net  and HIF-2α exert  a  synergistic  effect  on GAPDH transcription which 
seems to play a role in the hypoxic  regulation of the gene.  Their  trans-activating 
properties are restricted to non-tumorigenic 444 cells.
4.1.5  Siah 1 is not involved in the Net-HIF-2α mediated GAPDH 
transcriptional regulation
As outlined above, the Net-HIF-2α mediated transcriptional regulation of GAPDH is 
exclusively observed in non-tumorigenic cells. Two explanations are possible: first, 
the  post-translational  modifications  of  Net  and  HIF-2α  could  be  different  in  the 
investigated cell lines which would in turn influence the putative interaction of both 
factors or the recruitment of other trans-activating factors. Alternatively, the different 
response could be determined by the availability of a third, so far unknown factor or 
its post-translational modification status.
To  investigate  the  second  possibility,  the  impact  of  the  “seven-in-absentia 
homologue” Siah 1 on the Net and HIF-2α mediated synergism was studied. Several 
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properties of  Siah 1 support this model: Siah 1 and Siah 2 are both involved in the 
mediation  of  the  hypoxic  response  (Nakayama  et  al.,  2004).  These  E3-ubiquitin 
ligases  indirectly  mediate  the  stabilization  of  HIFs  via  the  ubiquitination  and 
subsequent  degradation  of  their  major  upstream  regulatory  factors,  the  prolyl-
hydroxylases  (PHDs).  In  addition,  they  have  been  suggested  to  play  a  so  far 
unknown role in the hypoxic regulation of Net (Gross et al., 2008). Altogether, Siah 1 
may be involved in the Net-HIF-2α mediated synergism of GAPDH transcription.
Initially, a possible role for Siah 1 in the post-translational modification of Net was 
investigated. Therefore, co-transfections of Net, Siah 1 or a ligase-deficient mutant, 
Siah 1C44S and  homeo-domain-interacting protein kinase 2 (HIPK2) were performed. 
HIPK2 is a well-known target of Siah 1-mediated proteasomal degradation and was 
included as a positive control.
Fig. 4.6: Siah 1 regulates post-translational modifications of Net. Co-transfections of 
Net, Flag-HIPK2, HA-Siah 1wt (“wt”) and its E3-ligase deficient mutant HA-Siah 1C44S (“C44S”) 
were performed in HEK 293. GFP was included to control the transfection efficiency. (A) 48 h 
after  transfection,  whole  cell  extracts  were  prepared  and  analyzed  by  Western  Blot.  “-”  
indicates control transfections without Siah 1. Flag-HIPK2 and HA-Siah 1 were detected with 
their appropriate protein-tag specific antibodies. (B) To determine, whether the doublet-band 
observed in the case of Net represents phosphorylated and unphosphorylated species, the 
control sample was subjected to λ-phosphatase treatment. Subsequently, equal amounts of 
dephophorylated (“Ph”) and untreated (“-”) sample were subjected to Western Blot analysis.
The Net antiserum applied in  Figure 4.3 B and  Figure 4.6 detects two differential 
post-translationally modified subspecies of Net.  In the absence of over-expressed 
Siah 1 preferentially the upper migrating form of Net is detectable (Fig. 4.6 A and B). 
This  changes  fundamentally  upon  co-expression  of  Siah 1wt:  Mainly  the  lower 
migrating form of  Net  is  visible.  Co-transfection  of  the E3 ligase-deficient  mutant 
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Siah 1C44S results in an intermediate band pattern. To identify the underlying post-
translational  modification,  λ-phosphatase  treatment  was  performed. 
Dephosphorylation lead to an accumulation of the lower migrating band (Fig. 4.6 B). 
Thus, the band-doublet represents phosphorylated and non-phosphorylated forms of 
Net, respectively. 
HIPK2 was included in the transfections as a positive control. Its ubiquitination and 
subsequent proteasomal degradation is mediated by Siah 1. Thus, the majority of 
HIPK2 is detectable in the absence of over-expressed Siah 1 (Fig. 4.6 A).
Although  equal  amounts  of  Siah 1wt and  its  mutant  were  transfected,  the  mutant 
seems to be more abundant than Siah 1wt  (Fig. 4.6 A). However, this is expected as 
Siah 1 is capable to auto-ubiquitinate itself  and thus mediate its own degradation 
(Lorick  et  al.,  1999).  Taken  together,  Siah 1  is  involved  in  the  post-translational 
regulation of Net.
Fig 4.7: Siah 1 does not have an impact on the Net-HIF-2α mediated transcriptional 
regulation of GAPDH. To monitor the effect of Siah 1 on a GAPDH-promoter driven firefly-
luciferase reporter, either Siah 1wt or Siah 1C44S alone or in combination with HIF-2α and Net 
were  co-transfected  in  444  and  CGL 3  and  subjected  to  24 h  hypoxia  (2 %  O2),  when 
indicated. The displayed values represent relative changes in the GAPDH-reporter activity 
normalized to a normoxic control sample and a co-transfected TK-renilla-luciferase reporter, 
which is not  regulated by Net and HIF-2α.   “N”  and “H” indicate  normoxia and 2 % O2, 
respectively.
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To  address  the  role  of  Siah 1  in  the  Net  and  HIF-2α mediated  transcriptional 
regulation  of  GAPDH,  luciferase  assays  were  performed.  According  to  Fig.  4.7, 
Siah 1 is not involved in the transcriptional regulation of GAPDH. Co-transfection of 
Siah 1 or its E3-ligase deficient mutant Siah 1C44S did not significantly change the 
GAPDH  reporter  activity  neither  under  normoxic  nor  under  hypoxic  conditions. 
Furthermore, the different response of the GAPDH-reporter in 444 and CGL 3 is not 
affected by Siah 1. As already shown in  Figure 4.5 B,  only hypoxia and the co-
transfection of Net and HIF-2α lead to a substantial induction of the GAPDH reporter 
in non-tumorigenic 444.
Summing up, Siah 1 does not seem to be involved in the transcriptional regulation of 
GAPDH in  non of  the tested conditions.  It  may however  play a role in the post-
translational regulation of Net phosphorylation.
4.2 Tumorigenic and non-tumorigenic cells differ in their response 
to chronic hypoxia
4.2.1  Impaired viability of tumorigenic cells upon hypoxia
Hypoxia, a severe reduction of the oxygen tension within the tissue, induces a variety 
of cellular adaption processes concerning for example metabolism, proliferation and 
angiogenesis. While it is generally accepted, that cancer cells develop mechanisms 
to  effectively cope with short  term and intermittent  hypoxia,  the situation is more 
complex in the case of chronic hypoxia, lasting from several hours to days (Bristow 
and Hill, 2008).
Previously  presented  results  already  indicate  a  different  hypoxic  response  of 
tumorigenic and non-tumorigenic cells. To decipher this observation in more detail,  
different assays were performed to monitor the hypoxic tolerance of the used cell 
lines.
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The universal cellular energy carrier ATP can be considered as a parameter reflecting 
cell  viability.  Considering that viable cells show only minor variations in their ATP 
levels, relative ATP levels could be used to determine the amount of viable cells in a 
culture (Izyumov et al., 2004). To determine the viability of the cell lines IMR 90, 444, 
CGL 3 and HeLa upon hypoxia, relative ATP levels were analyzed after 8 h at 1.5 % 
Fig. 4.8: Cellular ATP levels of CGL 3 and HeLa are largely impaired after 8 h hypoxia. 
IMR 90, 444, CGL 3 and HeLa were subjected to 8 h at 1.5 % O2 (“H”) or control conditions 
(“N”). Subsequently, ATP was quantified by a Luciferase-reporter based method using the 
CellTiter Glo kit (Promega). Luciferase units were normalized to the number of cells seeded.  
Depicted is the relative decrease as compared to the normoxic Luciferase activity.
Figure 4.8 indicates decreased ATP levels and thus a decrease of viable cells for all 
tested cell lines. However, the decrease is more prominent in the tumorigenic cell  
lines CGL 3 (67.3 %) and HeLa (49.3 %) than in the non-tumorgenic IMR 90 (29.9 %) 
and 444 (29.5 %). To distinguish, whether these results simply reflect hypoxic growth 
arrest or  induction of apoptosis, a FACS analysis of normoxic and hypoxic cells was 
performed.
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Fig. 4.9: HeLa cells show a dramatic increase of apoptosis upon hypoxia.  IMR 90, 444, 
CGL 3  and  HeLa  were  subjected  to  24 h  hypoxia  at  1.5 %  O2 (“H”)  or  normoxia  (“N”). 
Subsequently,  cells  were  fixed  for  FACS analysis.  Depicted  are  the  percentage  of  cells  in 
subG1. Error bars represent standard deviation of three independent experiments. 
The FACS analysis (Fig. 4.9) provides a more detailed picture of cell viability. Upon 
hypoxia, the non-tumorigenic cell lines IMR 90 and 444 show only a small increase of 
apoptosis: 4.4 % increase in IMR 90 and 1.9 % in 444. Notably, 444 already exhibits 
elevated levels of apoptotis under normoxia. The situation of the tumorigenic cells  
CGL 3 and HeLa is more complex: CGL 3 displays an 9.4 % increase of apoptotic 
cells upon hypoxia. But the most striking difference was observed in HeLa: after 24 h 
at 1.5 % O2, they show a 40.8 % increase of apoptosis as compared to normoxia. 
Altogether, ATP assay and FACS analysis point to a compromised cell viability in the 
tumorigenic CGL 3 and HeLa, with HeLa undergoing apoptosis to a large extent. The 
non-tumorigenic IMR 90 and 444 display only minimal increase of apoptosis and their 
ATP levels were less compromised under hypoxia. 
4.2.2  Elevated ROS levels in tumorigenic cells
A severe side effect of hypoxia is the occurrence of reactive oxygen species (ROS) at 
mitochondrial  complex  III  (Guzy  et  al.,  2005).  During  short  term and  intermittent 
hypoxia (lasting from minutes to hours) cancer cells develop efficient mechanisms to 
deal with the elevated ROS levels and the limited oxygen supply. Moreover, repeated 
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cycles of hypoxia and reoxygenation drive genomic instability resulting in an even 
more aggressive phenotype  (Cairns  et al.,  2001).  But is this also true for chronic 
hypoxia?
FACS analysis (Fig. 4.9) and ATP assay (Fig. 4.8) point to a reduced survival of 
tumorigenic cells  under  hypoxia.  To figure out,  whether  ROS are involved in  this 
process, 444, CGL 3 and HeLa were monitored for reactive oxygen species under 
normoxic and hypoxic conditions.
Fig.  4.10:  Tumorigenic cells exhibit elevated ROS levels. 444, CGL 3 and HeLa cells 
grown on  cover  slides were  subjected to  24 h  hypoxia  (1.5 % O2)  or  normoxia.  Prior  to 
fixation for immunofluorescence, 2.5 µM dihydroethidium (DHE) was added. ROS oxidized 
the DHE to a fluorescent dye, which was detected at 605 nm. The resulting images were 
converted to 16-colour code by the analysis software ImageJ. The scale in the lower part of  
the figure represents the semi-quantitative code for ROS levels.
Compared  to  non-tumorigenic  cells,  ROS  levels  are  already  elevated  in  the 
tumorigenic cell lines under normoxic conditions (Fig. 4.10): The majority of CGL 3 
and HeLa cells appears in yellow to red staining, indicating elevated ROS production. 
On the other hand, 444 cells show mainly a green to yellow staining reflecting a 
medium ROS production under normoxia (Fig. 4.10, upper part). This changes upon 
hypoxic treatment (Fig. 4.10, lower part):  Here, 444 are intensively red coloured 
indicating a strong increase of ROS. This is accompanied by a morphological change 
70
1.5 % O2
21 % O
2
444 CGL 3 HeLa
4. Results
towards a more elongated-spiky form which reflects the cellular stress. ROS levels in 
CGL 3 increase to an extent,  which exceeds the quantitative range of the assay. 
Morphologically, CGL 3 do not change as dramatic as 444. In HeLa cells, the ROS 
levels seem to be unchanged. The hypoxic shape of HeLa cells resembles the one of 
CGL 3. A closer look, however, reveals first signs of membrane blebbing in hypoxic 
HeLa cells which indicates apoptosis and confirms the FACS data (Fig. 4.9).
4.3  HPV and hypoxia
4.3.1  Viral gene expression under hypoxia
In the case of cervical cancer,  intratumoral hypoxia serves as a prognostic factor 
associated with a poor prognosis for patients. Despite the accumulating knowledge 
on therapeutic implications in the treatment of hypoxic  tumors, little is known about 
the regulation of HPV gene expression under these conditions. To get first insights 
into  the  expression  of  the  early  genes  E6  and  E7,  semi-quantitative  PCR  was 
performed.
Fig. 4.11: HPV E6/E7 expression is silenced upon hypoxia. Cells were subjected to 24 h 
normoxia  (“N”)  or  1.5 %  O2 (“H”),  cytosolic  RNA  was  prepared,  purified  from  DNA 
contamination and reverse transcribed. The expression of a HPV E6/E7 transcript and  β-
Tubulin was analyzed by semi-quantitative PCR.
Strikingly, the expression of HPV E6/E7 is silenced upon 24 h hypoxia. Moreover, all 
HPV-positive cells show this effect.  Comparing the normoxic E6/E7 expression of 
444, CGL 3 and HeLa, the tumorigenic cells display increased levels of the E6/E7 
transcript. As a normal fibroblast, IMR 90 does not show HPV expression, indicating 
PCR specificity.
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4.3.2  The impact of AP-1 in the hypoxic regulation of HPV 
expression 
The cellular transcription factor AP-1 plays a fundamental role in the transcriptional 
regulation  of  HPV  (Butz  and  Hoppe-Seyler,  1993).  In  particular,  its  dimeric 
composition is essential: While there is a high HPV E6/E7 expression expected in the 
presence of Jun-Fos dimers, the transcription of the early genes is reduced, when 
preferentially Fra-1 is incorporated into the AP-1 complex (Rösl et al., 1997; Soto et 
al.,  1999). To unravel, whether AP-1 is involved in the hypoxic down-regulation of 
HPV E6/E7, electromobility shift  assays (EMSA) were performed. Additionally,  the 
cellular expression of the cognate AP-1 subunits was monitored by Western Blot.
As shown in  Fig. 4.12 A, the analyzed cell lines IMR 90, 444, CGL 3 and HeLa do 
not fundamentally change their expression pattern of Fra-1, Fos and Jun. Rather, 
there is  in  some cases an increased expression of  the  AP-1 subunits  which  are 
already detectable under normoxia. This is in particular the case for Fra-1 in 444, Fos 
in  CGL 3  and  Jun  in  IMR 90  and  444.  The  upregulation  of  Fos  in  CGL 3  is 
accompanied by a change in the post-translational modifications, which might effect 
the trans-activating capacity of this transcription factor. Taken together, if Fra-1, Fos 
and Jun are not detectable under normoxia in the tested cell lines, hypoxia does not 
induce their expression. 
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Fig. 4.12: Hypoxia does not change the AP-1 composition. Cells were exposed to 1.5 % 
O2 (“H”) or normoxia (“N”) for 24 h and nuclear protein extract was prepared. 25 µg and 2  µg 
protein were analyzed by Western Blot (A) and EMSA (B), respectively.  Fra-1,  Fos, Jun,  
phospho-Jun (“pJun”) and Actin indicate antibodies used for immunodetection and supershift. 
To  determine  the  AP-1  composition  by  EMSA,  the  32P-labeled  AP-1  consensus 
oligonucleotide was initially incubated with the nuclear extract. To monitor the specific binding 
of AP-1 to the oligonucleotide, the binding was competed with an identical  but unlabeled 
probe (“c”). Subsequently, the antibody was included to target the indicated AP-1 subunit.  
Finally, the reaction mix was separated by PAGE, dried and exposed to a film. Supershifts 
are indicated by arrows. 
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However,  the  protein  levels  of  the  AP-1  subunits  do  not  necessarily  reflect  the 
composition of the dimeric complex. Thus, an EMSA-supershift was performed (Fig. 
4.12 B). It confirms the tendency of the Western Blot: There is not a change of the 
AP-1 composition. Rather, the overall AP-1 content in the cells changes preserving 
the original  composition.  In  444, the AP-1 composition is  mainly pJun-Fra-1.  The 
incorporation  of  both  factors  is  increased  upon  hypoxia,  reflecting  the  absolute 
increase of  AP-1  complex  formation  (Fig.  4.12  B,  lane  1  and 6).  In  CGL 3,  the 
amount of AP-1 complexes is similar under normoxia and hypoxia (lane 1 and  6). 
However, there seems to be an increased incorporation of Fos upon hypoxia (lane 4 
and 8), while there is only a minor change concerning pJun (lane 5 and 9). In HeLa, 
the EMSA even indicates a reduction of AP-1 complexes upon hypoxia (lane 1 and 
6), which is reflected by lower pJun incorporation (lane 5 and 9). However, the EMSA 
depicts an increased Fos incorporation into the AP-1 dimer upon hypoxia in HeLa 
(lane 4 and 8).
Taken  together,  neither  the  expression  of  the  tested  AP-1  subunits  nor  the 
composition of the AP-1 complex is basically changed upon hypoxia. Variations occur 
exclusively  in  the  expression  level  with  a  concomitant  enhanced  AP-1  binding. 
However, the composition of the complex remains identical compared to normoxia. 
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5.  Discussion
GAPDH, for a long time exclusively known as a glycolytic, ubiquitously expressed 
gene,  gained  attention  in  the  last  decade  when  scientists  unraveled  its  multiple 
functions in cell death and survival (Hara et al., 2005; Colell et al., 2007). Therefore it 
is not surprising that GAPDH expression seems to be deregulated in a variety of 
cancer types, including cervical cancer (Kim  et al.,  1998). To get insights into the 
underlying mechanisms, this study aimed to investigate the transcriptional regulation 
of  GAPDH  by  the  transcription  factors  HIF-2α and  Net,  as  previous  studies 
suggested their binding at the GAPDH promoter (Graven  et al., 2003; A. Hitschler, 
2007). Moreover, Net and HIF-2α  were linked to cancer development and mediate 
the hypoxic response (Wiesener  et al., 1998; Gross  et al., 2008). Considering the 
role of GAPDH as a trigger of cell death, its deregulation in cancer cells might be 
reflected by a worse survival of chronic hypoxia. In the context of HPV-positive cells, 
the viral oncogenes E6 and E7 may determine the hypoxic resistance. To get first 
insights,  their  expression  and  their  transcriptional  regulation  was  studied  under 
chronic oxygen deprivation.
5.1  Net and HIF-2α synergistically activate GAPDH transcription
5.1.1  GAPDH is differentially expressed in tumorigenic and non-
tumorigenic cell lines
As mentioned above, a different expression of GAPDH has been reported for multiple 
types  of  cancer,  including  breast  cancer  (Révillion  et  al.,  2000),  prostate  cancer 
(Epner  et  al.,  1993)  and  cervical  cancer  (Kim  et  al.,  1998).  Although  the  basal 
expression of GAPDH is frequently elevated in tumors, an impact of this deregulation 
on  hypoxic  GAPDH  expression  remains  elusive  so  far.  In  the  context  of  HPV-
associated cervical cancer, tumor hypoxia serves as a prognostic marker indicating 
poor patient outcome (Höckel  et al., 1993). Considering that GAPDH is involved in 
many metabolic processes and acts as a trigger between cell death and survival, a 
deregulated GAPDH expression under hypoxic conditions seems likely to occur in 
cervical cancer cells. 
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In order to unravel the relevance of an altered hypoxic GAPDH regulation, a model of  
HPV-positive  tumorigenic  (CGL 3)  and  non-tumorigenic  (444)  HeLa  x  fibroblast 
hybrids (Stanbridge, 1984) and their parental  homologues HeLa and IMR 90 were 
chosen.  The  hybrid  model  enables  the  comparison  of  molecular  events  in  a 
genetically identical background, as tumorigenic CGL 3 are spontaneous segregants 
of non-tumorigenic 444 after long-term cultivation. The parental cell lines IMR 90 and 
HeLa were included to allow conclusions about the origin of an observed phenotype. 
Furthermore,  this  model  reflects  different  stages  of  carcinogenesis:  IMR 90  is  a 
primary fibroblast cell line, reflecting HPV-negative non-transformed tissue (Nichols 
et al., 1977). 444 represents an intermediate state: as a HPV-positive hybrid cell line, 
it is immortal. Although these cells are non-tumorigenic, 444 display single oncogenic 
features like anchorage independent growth in soft agar (Stanbridge and Wilkinson, 
1980). In contrast, their tumorigenic counterparts CGL 3 and HeLa are able to form 
tumors in nude mice.
Initially, GAPDH expression was monitored on RNA level in both semi-quantitative 
(Fig 4.1 A) and quantitative PCR (Fig 4.1 B). Consistent with a deregulation of basal 
GAPDH expression during carcinogenesis,  GAPDH expression under  normoxia is 
elevated in CGL 3 and HeLa compared to IMR 90 and 444 (Fig 4.1 B). 
Hypoxic  GAPDH regulation  differs  between  non-tumorigenic  and  tumorigenic  cell 
lines, too (Fig 4.1 A). It seems, that 24 h of 1.5 % O2 induce a  profound upregulation 
of  GAPDH  in  the  non-tumorigenic  IMR 90  and  444  while  the  effect  in  their 
tumorigenic counterparts CGL 3 and HeLa is less pronounced. However, the semi-
quantitative  approach  is  error-prone.  To  verify  these  results,  three  independent 
sample  sets  were  analyzed  by  qPCR  (Fig 4.1  B).  Overall,  the  quantitative  data 
confirms the differences between tumorigenic and non-tumorigenic cell  lines.  The 
similar  behavior  of  IMR 90  and  444  leads  to  the  conclusion,  that  the  hypoxic 
regulation of  GAPDH is  unaltered in both cell  lines and mirrors the physiological 
response to hypoxia (Graven et al., 1998). More intriguingly, the tumorigenic cell lines 
HeLa and CGL 3 differ in their hypoxic GAPDH expression: CGL 3 show reduced 
GAPDH expression upon hypoxia,  whereas GAPDH expression  in  HeLa remains 
unchanged.  This  reflects  the  differences  observed  between  HeLa  and  CGL 3  at 
normoxic GAPDH levels and points to cell line specific regulatory changes.
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In conclusion, GAPDH transcription is deregulated in the tumorigenic cell lines HeLa 
and CGL 3. While basal GAPDH transcription seems to be generally elevated in the 
tumorigenic cells, CGL 3 and HeLa both lack the hypoxic GAPDH upregulation as 
observed in the non-tumorigenic cell lines IMR 90 and 444. 
5.1.2  Net and HIF-2α expression in HeLa x fibroblast hybrids is 
subject to multiple layers of regulation
To investigate the proposed mechanism of GAPDH transcriptional regulation in more 
detail, expression and promoter binding of the transcription factors Net and HIF-2α 
was monitored in the hybrid system 444 and CGL 3. As expected, both cell  lines 
showed a substantial accumulation of HIF-1α and HIF-2α protein after hypoxia (Fig. 
4.3  B).  This  effect  is  mediated  by  post-translational  stabilization  upon  oxygen 
deprivation, as the changes on protein level are not reflected by mRNA levels (Wang 
and Semenza 1993a; Wiesener et al., 1998). However, upon hypoxia, minor changes 
are observed in the mRNA levels of both HIFs (Fig. 4.3 A). In the case of HIF-1α, 
mRNA levels  slightly drop after  24 h chronic  hypoxia in  both  444 and CGL 3.  In 
contrast, HIF-2α levels seem to be slightly elevated in 444 and remain unchanged in 
CGL 3.  There  is  evidence,  that  both  transcription  factors  are  transcriptionally 
upregulated upon acute,  short-term hypoxia  lasting  from minutes  to  hours.  While 
chronic hypoxia (hours to days) does not affect the expression of  HIF-2α, the mRNA 
stability  of  HIF-1α  might  be  reduced  by  miRNA mediated  mechanisms  (Trash-
Bingham et al., 1999). Interestingly, an auto-negative feedback loop was proposed 
for this mechanism, involving the induction of an antisense transcript by both HIF-1α 
and HIF-2α and resulting in the exclusive destabilization of HIF-1α mRNA (Uchida et 
al., 2004) upon long-term hypoxia.
In contrast, Net expression dramatically differs between 444 and CGL 3. As reported 
previously, tumorigenic CGL 3 depict reduced Net expression while high Net levels 
are observed in non-tumorigenic 444 (Fig. 4.3 A and B) (van Riggelen et al., 2005). 
Moreover,  Net  protein  levels  in  CGL 3  are  further  diminished  upon  24 h  hypoxia 
which is not observed in their non-tumorigenic counterparts 444 (Fig. 4.3 B). Hypoxia 
was suggested to inhibit hydroxylation of Net leading to its subsequent proteasomal 
degradation (Gross et al., 2007). According to the absence of hypoxic Net regulation 
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in 444, this effect seems to be cell type dependent. In addition, hypoxic degradation 
of Net may rely on the severeness and duration of oxygen deprivation because the 
cited study of Gross et al. observed a complete loss of Net after 6 to 12 h at 1 % O2, 
whereas  the  present  study  applied  2 %  O2 for  24 h.  Thus,  decreasing  oxygen 
pressure would correlate with a decrease in Net stability.
To monitor the hypoxic response on mRNA level, VEGF expression was analyzed 
(Fig.  4.3 A).  As  reported  previously,  the  pro-angiogenic  VEGF is  transcriptionally 
upregulated  under  hypoxia  in  both  non-tumorigenic  444  and  tumorigenic  CGL 3 
(Forsythe  et  al.,  1996).  The  latter  ones  express  higher  basal  levels  of  VEGF in 
comparison  to  their  non-tumorigenic  counterparts.  Indeed,  VEGF  expression  is 
frequently  elevated  in  cancer  cells  and  it  correlates  with  high  vascularization  of 
cervical cancer (Kodama et al., 1999). 
In  conclusion,  the  analyzed  transcription  factors  Net,  HIF-1α  and  HIF-2α  are 
expressed in 444 and CGL 3, although in different levels depending on the cell line 
and the availability of oxygen. 
5.1.3  Hypoxia differentially regulates Net and HIF-2α binding to the 
GAPDH promoter in non-tumorigenic and tumorigenic cells
The transcription factors Net and HIF-2α mediate the cellular hypoxic response and 
were  suggested to  play a  role  in  GAPDH transcriptional  regulation.  According  to 
previous in silico analysis, the GAPDH promoter harbors multiple DNA binding motifs 
of Net. One of them (-248 to -227 bp upstream of the transcriptional start site) is 
located in close proximity to a previously described hypoxia response element (HRE) 
(-217 to -203 bp) (Hitschler, 2007; Lu et al., 2002) (Fig. 4.2). 
To  shed  light  on  the  binding  of  Net  and  HIF-2α  at  the  GAPDH promoter  under 
normoxia and 24 h hypoxia, a chromatin immunoprecipitation (ChIP) was performed 
(Fig. 4.4 A  and B).  The ChIP assay comprised two IP steps, a first  one directed 
against RNA Pol II and a second one targeting Net or HIF-2α. This approach allowed 
fishing of actively transcribed promoters bound by the specific transcription factors. 
Especially in the case of Net this approach is interesting, as previous studies focused 
only  on  its  repressive  properties.  However,  it  was  suggested  to  act  as  a  trans-
activator for other genes, too (Giovane et al., 1994). A drawback of the pre-selection 
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of RNA Pol II bound promoters is the potential correlation of RNA Pol II promoter 
binding with the rate of transcription and the resulting mRNA levels. According to a 
simplified model, the limiting factor of transcription is the recruitment of RNA Pol II to 
the promoter and not its time of retention at the transcriptional start site. In the first 
case, variations of RNA Poll II promoter binding would influence the result of the ChIP 
assay. However, as a constitutive and highly expressed gene, GAPDH is generally 
bound by RNA pol  II.  Differences in  GAPDH mRNA levels  rather  result  from the 
speed of RNA Pol II promoter clearance than the rate of RNA Pol II recruitment to the 
promoter (Rougvie et al., 1990). The efficiency of RNA Pol II hyperphosphorylation, 
representative for active RNA Pol II in most cases, does not account for the rate of 
transcription of housekeeping genes neither, as hypophosphorylated forms of RNA 
Pol II were shown to participate in their transcription, too (Weeks et al., 2010). In fact, 
there is  supposedly a chain of differentially phosphorylated RNA Pol  II  along the 
transcriptional start site of GAPDH. Therefore, the amount of active RNA Pol II bound 
to the GAPDH promoter is considered to be constant and does not reflect changes in 
the transcriptional activity of the gene. 
How do Net and HIF-2α influence the transcription of GAPDH? According to their 
promoter  binding  under  normoxia  and  hypoxia,  there  seems  to  be  a  differential 
response to hypoxia in non-tumorigenic 444 compared to tumorigenic CGL 3  (Fig. 
4.4 B). While hypoxia increases Net and HIF-2α binding at the GAPDH promoter in 
444, only minor changes happen in the case of CGL 3 after 24 h at 2 % O2. Taking 
into  consideration  that  the  expression  of  GAPDH  is  increased  under  hypoxia 
exclusively 444 while it is even reduced in CGL 3 (Fig. 4.1 B), it could indicate a 
trans-activating  role  of  Net  and HIF-2α in  GAPDH transcription.  Interestingly,  the 
promoter binding of both transcription factors is not reflected by their absolute protein 
levels  determined  by Western  Blot  (Fig.  4.3  B).  While  Net  expression  in  444  is 
unchanged  upon  hypoxia,  its  promoter  binding  is  increased.  Similarly,  the  slight 
reduction of overall Net protein levels upon hypoxia in CGL 3 is not reflected by the 
the extent of promoter binding, which remains unchanged.  In the case of HIF-2α, the 
effect is even more striking: While the protein is undetectable under normoxia by 
Western Blot, ChIP assay determines substantial amounts of HIF-2α at the GAPDH 
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promoter under these conditions. Thus, the promoter binding of Net and HIF-2α is 
probably determined by additional mechanisms, which may influence their impact on 
GAPDH transcription. 
5.1.4  Net and HIF-2α synergistically activate GAPDH transcription 
exclusively in non-tumorigenic cells
A possible synergistic effect of Net and HIF-2α on GAPDH transcription is supported 
by previous studies on Net related proteins: the transcription factors Elk-1 and Ets-1, 
which belong to the same protein family as Net, were shown to cooperate with HIF-
2α (Aprelikova et al., 2006, Elvert et al., 2002). In this case, the protein interaction is 
facilitated by their shared helix-loop-helix (HLH) domain which Elk-1 and Ets-1 have 
in common with Net. Moreover, the in silico predicted distance of Net and HIF-2α cis-
regulatory elements within the GAPDH promoter matches the maximal spacing of 
60 bp, which was previously reported as a common feature of Ets factor and HIF-2α 
mediated gene regulation.
To decipher the impact of Net and HIF-2α on GAPDH transcription in more detail,  
Luciferase  reporter  assays  were  performed  (Fig.  4.5).  Here,  three  important 
characteristics of Net and HIF-2α mediated GAPDH transcriptional regulation were 
revealed:  First,  Net  and  HIF-2α  exert  a  trans-activating  synergism  on  GAPDH 
transcription. The effect is exclusive for both proteins as HIF-1α cannot substitute for 
HIF-2α (Fig. 4.5 A). Secondly, the synergism can be further augmented by hypoxia 
(Fig.  4.5  B).  Thirdly,  only  non-tumorigenic  444  display  the  effect.  Neither  co-
transfection of Net  and HIF-2α nor induction of  hypoxia significantly changes the 
reporter  activity  in  CGL 3  (Fig.  4.5  A  and B).  Nevertheless,  the  physiological 
relevance of reporter assays is limited, as they only analyze the regulatory effect of  
over-expressed  transcription  factors  on  an  approximately  1000 bp  promoter 
fragment,  which neglects the endogenous genomic environment and the interplay 
with other endogenous transcription factors. To rule out artificial side effects of the co-
transfected  proteins,  the  activity  of  the  GAPDH  reporter  was  monitored  in  the 
absence  of  over-expressed  Net  and HIF-2α.  Strikingly,  the  reporter  was  induced 
upon hypoxia exclusively in 444 (Fig. 4.5 B) which reflects the hypoxic upregulation 
of endogenous GAPDH in the non-tumorigenic cell lines IMR 90 and 444 (Fig. 4.1) 
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and underlines the physiological relevance of these results. Over-expression of Net 
and  HIF-2α indeed further augments the reporter activity in 444 under both normoxic 
and  hypoxic  conditions.  Accordingly,  both  proteins  might  exert  a  trans-activating 
synergism on physiological GAPDH transcription, which probably participates in the 
hypoxic regulation of GAPDH transcription.
However, the question remains whether different Ets factors might influence GAPDH 
transcription. Hollenhorst and colleagues propose a model, where Ets transcription 
factors  facilitate  both  general  high  transcription  and  trigger  specific  regulation 
depending on the properties of the Ets DNA binding site (EBS) (Hollenhorst  et al., 
2007). In the case of GAPDH transcriptional regulation, both features are possible. 
The  above  described  Net-HIF-2α  synergism  is  likely  to  be  a  gene  specific 
mechanism,  leading  to  the  recruitment  of  a  specific  Ets  factor  to  the  GAPDH 
promoter. However, it cannot be excluded that other Ets factors which are able to  
interact  with  HIF-2α,  too,  could  substitute  for  Net.  Possibly,  such  a  mechanism 
enables the integration of different signaling pathways by multiple Ets factors. Post-
translational modifications might determine which Ets factor is preferentially bound by 
HIF-2α and concomitantly which Ets factor mainly regulates gene transcription. In the 
context of the present study, it remains to be elucidated, how different Ets factors 
regulate  the  GAPDH  transcription  in  tumorigenic  and  non-tumorigenic  cells  and 
whether they are able to synergize with HIF-2α in that context. 
In  contrast  to  Ets  factors,  HIFs  mediate  the  hypoxic  response  in  a  highly  gene-
specific  manner.  Both,  HIF-1α  and  HIF-2α  are  involved  in  the  transcriptional 
regulation of GAPDH in a context dependent manner (Graven et al., 1999 and 2003). 
Under long-term, chronic hypoxia, HIF-1α protein levels decrease while HIF-2α is 
constantly expressed (Uchida  et al.,  2004) enabling a differential activation of HIF 
target genes according to the extent and duration of hypoxia. The observed Net-HIF-
2α synergistic activation of GAPDH (Fig. 4.5) might therefore predominantly play a 
role under long-term hypoxia. In addition, a transcriptional regulation of GAPDH by 
both HIFs would partially explain the different extent of hypoxic GAPDH activation on 
mRNA level (Fig. 4.1) and in the luciferase-reporter assay (Fig. 4.5). The latter one 
monitors  the  effect  of  over-expressed  HIF-2α  on  the  reporter  construct, 
representative  for  chronic  hypoxia  and  independent  of  endogenous  factors.  In 
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contrast, the GAPDH qPCR reflects the  in vivo transcriptional regulation influenced 
by  the  duration  and  extent  of  hypoxia,  the  genomic  environment  and  post-
transcriptional mechanisms. Future studies will be required to figure out the specific 
contribution of the Net and HIF-2α synergism on GAPDH transcription. To decipher 
whether the duration of hypoxia influences the synergism, additional GAPDH-reporter 
assays may be required.
Overall,  the important cellular functions of GAPDH require both a high but tightly 
regulated transcription. Thus, it is not surprising that HIFs and Ets factors themselves 
are able to integrate different context dependent signals on GAPDH transcription. 
The specific contribution of the Net-HIF-2α synergism requires further investigation. 
There is evidence, that it might be involved in the GAPDH transcriptional regulation 
during chronic hypoxia.
5.1.5  Possible mechanisms determining the Net-HIF-2α synergism
As discussed above, the reporter assay depicts striking differences in the GAPDH 
transcriptional regulation between 444 and CGL 3. This observation is supported by 
the results of the ChIP assay (Fig. 4.4) and the endogenous GAPDH expression 
(Fig. 4.1) which display as well a different response to hypoxia in 444 and CGL 3. 
What could be causative for this observation? Mutations of the GAPDH promoter in 
either  CGL 3  or  444  might  alter  the  affinity  of  the  cis-regulatory  element  to  the 
respective transcription factor. However, this possibility can probably be excluded, as 
the data from ChIP and qPCR experiments corresponds to the reporter assay data. 
Furthermore,  the  post-translational  modifications  of  either  Net  or  HIF-2α may be 
different in the cell lines which  influences the recruitment of co-activators. In addition, 
a third co-factor could be required for the synergistic transcriptional activation by Net 
and HIF-2α, which might be differentially regulated in both cell lines. 
Possible factors which might play a role in the Net and  HIF-2α synergism are the 
“seven in absentia” homologues Siah 1 and Siah2. They are involved in the HIF-
mediated  hypoxic  response  and  were  recently  suggested  to  participate  in  Net 
regulation (Nakayama  et al.,  2004; Gross  et al.,  2008). Therefore, overexpression 
studies including Net, Siah 1 and HIPK2 as a positive control for Siah 1 E3-ligase 
activity  were  performed (Fig.  4.6  A).  It  was  shown that  co-expression  of  Siah 1 
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reduced  Net  phosphorylation  (Fig.  4.6  A  and B).  Possibly,  Siah 1  targets  an 
upstream kinase of Net for proteasomal degradation, which would explain the lack of 
Net phosphorylation in the presence of over-expressed wild-type Siah 1. However, 
this model does not apply to the fact, that co-expression of the E3-ligase-deficient 
Siah 1C44S mutant as well reduces the phosphorylation of Net, although to a lesser 
extent than the wild-type Siah 1 does. Alternatively, Siah 1 could act as an adapter 
protein for the recruitment of Net regulators. According to that model, the activity of 
Siah 1 would only be partially dependent on its E3-ligase function, as the putative 
adapter properties of the ligase-deficient Siah 1C44S seem to be slightly impaired. In 
addition,  it  cannot  be excluded that  the C44S amino acid  substitution affects the 
protein conformation of the Siah 1 mutant. E3-ligase independent functions of Siah 1 
are indeed described in the literature. It has been reported to act as a transporter, 
facilitating nuclear translocation of proteins (Hara et al., 2005). 
To clarify the role of Siah 1 in the Net-HIF-2α  trans-activating synergism, GAPDH-
reporter  assays  were  performed.  However,  Siah 1  did  not  significantly  effect  the 
activity of the Luciferase-reporter (Fig. 4.7). Thus, Siah 1 is probably not involved in 
the Net-HIF-2α mediated transcriptional regulation of GAPDH. 
According  to  the  over-expression  studies  described  above  (Fig.  4.6  A),  another 
explanation  may  be  possible.  As  a  positive  control  for  the  E3-ligase  function  of 
Siah 1, the kinase HIPK2 was included in the co-transfections and it cannot be ruled 
out that HIPK2 directly phosphorylates Net. High levels of HIPK2 correlate with an 
accumulation of phospho-Net. In contrast, overexpressed wild-type Siah 1 facilitates 
proteasomal  degradation  of  HIPK2,  which  results  in  a  reduction  of  the 
phosphorylated Net species. To date, an interaction of Net and HIPK2 has not yet 
been described. However, a possible link may be their common involvement in the 
SUMO-pathway. Net was previously described to interact with the SUMO E3-ligase 
PIAS1, which enhances the repressive properties of Net (Wasylyk  et al., 2005). In 
turn, HIPK 2 has been shown to be SUMOylated itself, which potentiates its  trans-
repressive properties (Roscic et al., 2006).  Future experiments are required to clarify 
the possible  role  of  HIPK2 in  Net  regulation.  A GAPDH-luciferase reporter  assay 
including Net, HIF-2α, HIPK2 and a kinase-deficient HIPK2 mutant might give further 
insights.
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Additionally,  certain  post-translational  modifications  of  Net  and  HIF-2α  may  be 
required for the synergistic transcriptional activation of GAPDH. These modifications 
could be different in 444 and CGL 3 which may explain the absence of the synergism 
in the latter cell line. However, protein analysis of Net and HIF-2α by Western Blot did 
not point to differences in post-translational modifications, as the migration pattern of 
both factors was similar  in  both cell  lines (Fig.  4.3 B)  and did  not  change upon 
hypoxia  neither.  Considering  that  certain  post-translational  protein  modifications 
might  interfere  with  the  binding  of  Net  and HIF-2α specific  antibodies  applied  in 
Western Blot, cell line dependent differences in the post-translational modifications of  
these factors cannot be excluded.
Overall,  there  is  no  evidence  for  a  role  of  Siah 1  in  the  Net-HIF-2α  synergistic 
regulation of GAPDH expression. Possibly certain post-translational modifications of 
Net and HIF-2α are prerequisite for their impact on GAPDH transcription. Moreover, a 
role of HIPK2 seems to be possible and may be subject for future investigations.
5.2  The role of GAPDH in the survival of chronic hypoxia
5.2.1  Chronic hypoxia sensitizes tumorigenic cells to oxidative and 
energetic stress
GAPDH exerts a number of pro- and anti-apoptotic functions and was suggested to 
act as a checkpoint control, which initiates cell death upon aberrant signaling (Colell  
et al., 2009).  As expected, GAPDH transcription is deregulated in the cervical cancer 
cell line HeLa and the HeLa x fibroblast hybrid CGL 3. To investigate whether this 
observation correlates with an altered cellular survival under long-term hypoxia, cell  
viability was monitored by FACS (Fig. 4.9) and ATP (Fig. 4.8) assay.  Whereas the 
viability of non-tumorigenic IMR 90 and 444 is only minimally altered, the cell integrity 
is severely compromised in the tumorigenic CGL 3 and HeLa. According to the FACS 
assay, more than 40 % of the monitored HeLa cells undergo apoptosis during 24 h 
hypoxia (Fig. 4.9). Although the percentage of apoptotic cells is also increased in 
CGL 3 upon hypoxia, it does not exceed 10 %. This is in contrast to the cell viability 
determined by the ATP assay (Fig. 4.8), which indicates the most prominent drop for 
CGL 3. This obvious discrepancy could be explained by other forms of cell death like 
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necrosis.  Indeed,  hypoxic  cell  death  can  result  both  in  apoptosis  and  necrosis, 
dependent on the cellular ATP content (Shimizu et al., 1996). Execution of apoptosis 
requires sufficient amounts of ATP for chromatin laddering, membrane blebbing and 
nuclear condensation. Therefore it is normally induced, when  ATP levels are within a 
certain range (Smets et al., 1994). However, when apoptosis is inhibited or in case of 
severe ATP depletion, necrosis occurs. As mentioned above, CGL 3 cells display a 
more prominent drop of ATP compared to HeLa while there is only a minor increase 
of apoptosis. According to the ATP dependent cell death model, a sub-population of 
CGL 3 might retain sufficient amounts of ATP to undergo apoptosis, while the other 
ones blunted from ATP die of necrosis. This may explain why there is only a small 
increase of apoptotic cells under hypoxia (Fig. 4.9) despite the most prominent drop 
of  cell  viability  (Fig.  4.8).  Interestingly,  Steinbach and colleagues report  hypoxia-
induced necrosis in an apoptosis competent cell model which implicates that there 
exist  anti-apoptotic  mechanisms  preventing  cell  death  as  long  as  mitochondrial 
integrity and energy homeostasis are maintained and may describe the situation in 
CGL 3  (Nafz  et  al.,  2007).  Indeed,  necrosis  is  the  predominant  cell  death  within 
poorly vascularized tumor areas (al-Nafussi and Hughes, 1994). 
However, the question remains why cancer cells are more susceptible to the energy 
stress  of  chronic  hypoxia.  In  untransformed  cells,  an  increased  AMP/ATP  ratio, 
indicating  a  low energy state,  causes  activation  of  AMP-activated  protein  kinase 
(AMPK).  The  kinase  subsequently  induces  downstream  pathways  like  mTOR 
required  to  restore  energy  homeostasis.  Essential  for  activation  of  AMPK  is  its 
phosphorylation  by  the  upstream  kinase  LKB1  which  is  not  expressed  in  the 
tumorigenic cells HeLa and CGL 3 (Shaw  et al., 2004; Nafz et al., 2007). Loss of 
LKB 1 causes aberrant elevated mTOR signalling which may promote tumorigenesis 
by facilitating cell proliferation independent of cellular energy levels. In contrast to 
HeLa and CGL 3, the non-tumorigenic 444 express LKB 1. Under chronic hypoxia 
they are therefore able to adapt to the falling energy levels which ensures cellular  
survival. HeLa and CGL 3 do not sense these alterations, driving them into metabolic 
catastrophe and cell death. Interestingly, oxygen deprivation itself is able to induce 
AMPK  which  is,  however,  not  mediated  by  LKB1.  Rather,  CAMKK2,  another 
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upstream  kinase  of  AMPK,  seems  to  facilitate  the  oxygen  dependent  activation 
(Høyer-Hansen and  Jäätelä,  2007).  Notably,  differences in  the  CAMKK2 function 
between 444, CGL 3 and HeLa remain elusive.
Other explanations may apply for the mainly apoptotic cell death observed in HeLa 
(Fig.  4.9).  Their  apoptosis  is  probably  triggered  by  other  mechanisms  than  ATP 
depletion.  Alternative causes would be accumulating cell  damage due to reactive 
oxygen species, which are excessively released from the mitochondria upon hypoxia. 
Indeed, hypoxia triggers an increased ROS production in 444 and CGL 3 (Fig. 4.10 
lower line).  In HeLa, however, ROS levels of the viable cells remain unchanged. 
Thus, it is possible that HeLa is not able to tolerate an hypoxic elevation of ROS 
which correlates with the observed increase of apoptosis under hypoxia (Fig. 4.9). 
Furthermore, excessive ROS levels are known inducers of apoptosis in HeLa cells 
(Singh  et  al.,  2007).  In  turn,  the  elevated ROS levels  displayed  in  viable  CGL 3 
contradict a causative role of oxidants in their sensitivity to chronic hypoxia (Fig. 4.10 
lower line). The underlying mechanisms for the different tolerance of oxygen radicals 
in  CGL 3  and  HeLa  remain  elusive.  Several  explanations  are  possible:  Minor 
differences in their p53 levels may be causative as low p53 levels sensitize cells for 
ROS induced DNA damage (Kim  et al., 1997). Moreover, the quality of their DNA 
repair (Bindra  et al., 2007), the regulation of anti-oxidant enzymes (Pelicano  et al., 
2004) and the tolerance of misfolded proteins due to oxidative damage (Wouters and 
Koritzinsky, 2008) are further aspects influencing the susceptibility to ROS.
Taken  together,  the  survival  of  chronic  hypoxia  differs  in  non-tumorigenic  and 
tumorigenic cells. While 444 and IMR 90 display only a minor drop of cell viability and 
no  significant  increase  in  apoptosis  upon  hypoxia,  the  tumorigenic  counterparts 
CGL 3 and HeLa seem to be severely impaired. However, they themselve show a 
different biological outcome: while HeLa massively undergo apoptosis, CGL 3 may 
turn  into  necrosis.  As  the  cell  death  observed  upon  chronic  hypoxia  is  probably 
caused by ATP depletion or excessive ROS levels  rather than prolonged oxygen 
deprivation  per se,  these findings do not contradict the hallmark that cancer cells 
have acquired an increased resistance to hypoxic pressure (Graeber  et al., 1996). 
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Notably,  after 24 h  in vitro hypoxia, a subpopulation of CGL 3 and HeLa was still 
viable in  this  study.  Thus,  repeated cycles  of  chronic  hypoxia  could  promote the 
selection of a hyper-resistant and more aggressive cancer phenotype.
5.2.2  The role of GAPDH in chronic hypoxia
Taken together, the results of the present study indicate a reduced survival of the 
tumorigenic cell lines CGL 3 and HeLa under  in vitro long-term hypoxia correlating 
with  the  absence  of  the  hypoxic  upregulation  of  GAPDH by Net  and  HIF-2α.  In 
contrast, the hypoxic GAPDH response in the non-tumorigenic 444 and IMR 90 is 
accompanied by a non-impaired cell viability. Considering the role of GAPDH as a 
trigger in cell death and survival, it is tempting to speculate about its crucial functions 
under chronic hypoxia.
The hypoxic upregulation of GAPDH in the non-tumorigenic cells may certainly be 
required for the maintenance of the energy homeostasis as hypoxic upregulation of 
glycolytic enzymes is a well-described phenomenon and renders cells independent of 
the oxygen supply (Semenza  et al., 1994). In addition, GAPDH can itself regulate 
metabolism. Recently, the enzyme was shown to inactivate the mTOR pathway under 
low-glucose conditions which might be important for the adaption to chronic hypoxia 
as well (Lee et al., 2009). Considering the hypoxic elevation of ROS levels observed 
in 444, GAPDH could be oxidized at its catalytic site, leading to a partial block of 
glycolysis and a subsequent rerouting of the glycolytic intermediates into the pentose 
phosphate  pathway  which  fuels  the  antioxidant  response  (Ralser  et  al.,  2007). 
Moreover, a translocation of GAPDH to the nucleus could be required to stabilize 
mediators of the DNA damage response and thus prevent genomic instability (Azam 
et al., 2008). According to this versatile role, it is evident why GAPDH upregulation 
may  be  beneficial  to  survive  chronic  hypoxia:  energy  depletion,  massive  ROS 
accumulation and  DNA damage are well-known triggers for cell death.
In contrast,  the tumorigenic cell  line CGL 3 and HeLa display an altered GAPDH 
response  to  chronic  hypoxia.  The  data  of  the  GAPDH-luciferase  reporter  assays 
suggest that CGL 3 and HeLa are not able to upregulate GAPDH under hypoxia at all  
(Fig. 4.1 and Fig. 4.5). This inability may render CGL 3 unable to increase glycolysis 
upon hypoxia and could thus be causative for the ATP depletion observed in CGL 3 
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(Fig.  4.8).  As cancer  cells,  HeLa and CGL 3 are  optimized for  proliferation  even 
under  harsh  environmental  conditions,  when  nutrients  and  oxygen  are  scarce. 
Indeed, the ability of cancer cells to sense declining ATP levels is often impaired 
(Nafz et al., 2007; Shaw et al., 2004). As mentioned above, GAPDH itself is able to 
trigger  shut-down  of  the  mTOR  pathway.  Under  conditions  of  transient  energy 
depletion,  maintaining  the  mTOR  signaling  might  provide  a  growth  advantage. 
Considering,  that  the  mTOR inhibition  and  the  glycolytic  function  of  GAPDH are 
exclusive, keeping GAPDH in glycolysis may promote cell growth under conditions of 
limited energy (Lee et al., 2009). 
Taken  together,  hypoxic  GAPDH  upregulation  is  a  normal  part  of  the  hypoxic 
response  in  the  non-tumorigenic  cell  lines  and  ensures  survival  under  these 
conditions. On the other hand, the lack of the GAPDH response to hypoxia may 
contribute  to  the  sensitivity  of  tumorigenic  cell  lines  to  in  vitro chronic  hypoxia. 
However, it cannot be excluded, that the maintenance of basal GAPDH levels in the 
cytosol may serve as a growth advantage under transient oxygen deprivation.
5.3  Hypoxic regulation of HPV18
Hypoxia is a poor prognostic factor for the therapy of cervical cancer patients which 
underlines  the  necessity  to  understand  the  contributing  molecular  mechanisms 
(Höckel  et al.,  1993). In the case of cervical carcinomas, this includes knowledge 
about  the  hypoxic  regulation  of  HPV  expression,  as  the  viral  oncoproteins  are 
causative  for  these  tumors.  Hypoxic  incubation  for  24 h  resulted  in  a  complete 
silencing of the viral early genes in non-tumorigenic and tumorigenic HPV-positive 
cells (Fig. 4.11). Assuming a transcriptional mechanism for HPV down-regulation, the 
impact  of  its  main  transcriptional  regulator  AP-1  was  studied.  However,  the 
composition of the AP-1 complexes did not change which is in agreement with the 
expression  of  the  cell  line  specific  subunits.  Rather  the  overall  amount  of  AP-1 
complexes was altered (Fig. 4.12). In conclusion, AP-1 does not seem to mediate the 
hypoxic response of HPV 18, raising the question for other factors which might be 
involved.
A potent inhibitor of HPV transcription under these circumstances could be NFκB. 
Binding  of  NFκB  to  the  viral  URR  was  shown  to  block  HPV 16  early  gene 
88
5. Discussion
transcription (Fontaine  et al. 2000). However it is not clear whether NFκB exerts a 
similar effect on HPV 18 as some aspects of the transcriptional regulation of HPV 16 
do  not  apply  for  HPV 18.  To  date  it  is  unclear  what  determines  the  repressive 
properties of NFκB in the case of HPV as NFκB is mainly reported to act as a trans-
activator  and  both  ROS and  hypoxia  are  potent  activators  of  NFkB  (Taylor  and 
Cummins, 2009). 
Energy  depletion,  caused  by  treatment  with  2-deoxyglucose  or  low  glucose 
conditions was previously reported to cause a down-regulation of HPV mediated by 
different alterations of the  trans-activatior Sp-1 (Maehama et al., 1998; Kang et al., 
2003). Indeed, Kang and colleagues show absence of Sp-1 binding at the HPV 18 
URR upon  hypoxia.  However,  it  is  still  unclear,  whether  absence  of  Sp-1  is  the 
primary cause for the efficient down-regulation of HPV expression or whether other 
transcription factors participate in this action. It is possible, that hypoxia induces DNA 
binding of a potent transcriptional repressor of the viral URR which blocks the GC 
box  (the  Sp-1  DNA motif).  Similar  mechanisms  lead  to  the  inhibition  of  HPV 
transcription by its viral inhibitor E2 (Tan et al., 1994).
Hypoxic silencing of HPV seems to be a general effect irrespective of tumorigenicity.  
Hypoxic loss of the viral oncoproteins might lead to a restabilization of pRB and p53. 
Indeed,  hypoxia  was  shown  to  cause  an  accumulation  of  p53  in  E6-positive 
keratinocytes (Kim et al., 1997). p53 may subsequentially facilitate the DNA damage 
response  triggered  by  hypoxic  ROS.  However,  stabilization  of  p53  upon  oxygen 
deprivation increases the cellular susceptibility to apoptosis.  Hypoxic loss of viral E7 
expression allows reactivation of pRB which in turn attenuates cell cycle progression 
upon hypoxia. Considering that cell proliferation requires stable energy supply and 
abolishes fixation  of  hypoxic  DNA damage,  reactivation  of  pRB may prevent  cell 
death. However, E6/E7 expressing keratinocytes display an increased sensitivity to 
hypoxia which implies the necessity for further transforming events during cervical 
carcinogenesis (Kim  et  al.,  1997).  Indeed,  the anti-apoptotic  factor  Bcl-2  is  over-
expressed in advanced cervical lesions (Saegusa et al., 1996) and mediates cellular 
resistance to hypoxia (Liang et al., 1995). 
Taken together, it is unclear which transcription factors are involved in the hypoxic 
silencing  of  HPV early  gene  expression.  Yet,  different  compositions  of  the  AP-1 
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complex do not seem to play a role. Sp-1 and NFκB are possible candidates which 
could be involved. Further research will be required to clarify their impact on hypoxic 
HPV silencing and how these events influence the hypoxic phenotype of cervical 
tumors.
5.4  Conclusion
GAPDH was suggested to act as a trigger between cell death and survival and its 
deregulation was proposed to play an important role during tumorigenesis. Indeed, 
this study depicts a deregulation of both basal and hypoxic GAPDH transcription in 
tumorigenic  CGL 3  and  HeLa.  In  non-tumorigenic  cells,  the  hypoxic  increase  of 
GAPDH expression was synergistically mediated by Net and HIF-2α which correlates 
with their increased hypoxic binding at the GAPDH promoter. Either a modified post-
translational regulation of Net and HIF-2α or the requirement of a third factor which is 
deregulated  in  cancers  might  disable  the  synergistic  activation  of  GAPDH  in 
tumorigenic cells. Future studies will be required to clarify this issue.
The differential transcriptional regulation of GAPDH under chronic hypoxia in non-
tumorigenic and tumorigenic cells may have an impact on their survival under these 
conditions. Hypoxic upregulation of GAPDH in non-tumorigenic cells correlates with a 
better cell viability. In turn, the tumorigenic cell lines HeLa and CGL 3 which do not 
increase  their  GAPDH  expression,  display  a  highly  impaired  cell  viability  upon 
hypoxia. However, high levels of apoptosis are exclusively observed in HeLa while 
CGL 3 depict only a small increase of apoptotic cells upon hypoxia despite poor cell 
viability. Thus, other forms of cell death like necrosis may be involved. Overall, the 
data  supports  a  general  sensitivity  of  cervical  cancer  cells  to  energy  depleting 
conditions. The fact that nutrient depletion might contribute to the observed sensitivity 
of  tumorigenic cells to chronic hypoxia resolves the apparent  contradiction to the 
hallmark  that  cancer  cells  are  more  resistant  to  oxygen  deprivation  than  non-
tumorigenic cells. In the studied cell lines, GAPDH might therefore act as a sensor of 
oxygen and nutrient depletion which maintains energy homeostasis by its glycolytic 
properties,  by counteracting cell  proliferation and by promoting energy preserving 
mechanisms like autophagy.
Another determinant of cellular survival are the viral oncogenes E6 and E7. Their 
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expression is silenced upon hypoxia in all tested HPV-positive cell lines irrespective 
of  their  tumorigenicity.  Although  AP-1  could  be  excluded  as  causative  for  these 
events, other transcription factors like NFκB and Sp-1 might be involved. How the 
hypoxic loss of viral oncogene expression influences hypoxic resistance of cervical 
cancer requires further investigation. 
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